| Year |
Citation |
Score |
| 2023 |
Ganguly S, Lone Z, Muskara A, Imamura J, Hardaway A, Patel M, Berk M, Smile TD, Davicioni E, Stephans KL, Ciezki J, Weight CJ, Gupta S, Reddy CA, Tendulkar RD, et al. Intratumoral androgen biosynthesis associated with 3β-hydroxysteroid dehydrogenase 1 promotes resistance to radiotherapy in prostate cancer. The Journal of Clinical Investigation. 133. PMID 37966114 DOI: 10.1172/JCI165718 |
0.377 |
|
| 2023 |
Stoyanova R, Zavala-Romero O, Kwon D, Breto AL, Xu IR, Algohary A, Alhusseini M, Gaston SM, Castillo P, Kryvenko ON, Davicioni E, Nahar B, Spieler B, Abramowitz MC, Dal Pra A, et al. Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI. Cancers. 15. PMID 37958414 DOI: 10.3390/cancers15215240 |
0.32 |
|
| 2023 |
Handke A, Kesch C, Fendler WP, Telli T, Liu Y, Hakansson A, Davicioni E, Hughes J, Song H, Lueckerath K, Herrmann K, Hadaschik B, Seifert R. Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy. Journal For Immunotherapy of Cancer. 11. PMID 37857524 DOI: 10.1136/jitc-2023-007354 |
0.385 |
|
| 2023 |
Chua MLK, Hakansson AK, Ong EHW, Hong BH, Miao JJ, Sim AYL, Tan JSH, Tan KM, Lee GCJ, Low KP, Tuan JKL, Tan TWK, Wang MLC, Yeong JPS, Tan MCS, ... ... Davicioni E, et al. Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race-specific luminal-basal and microenvironmental differences. Cancer Communications (London, England). PMID 37700560 DOI: 10.1002/cac2.12467 |
0.41 |
|
| 2023 |
Bitting RL, Wu Y, Somarelli JA, Proudfoot JA, Liu Y, Davicioni E, George DJ, Armstrong AJ. Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial. Jco Precision Oncology. 7: e2300214. PMID 37595184 DOI: 10.1200/PO.23.00214 |
0.406 |
|
| 2023 |
Solanki AA, Yoo RK, Adams W, Davicioni E, Mysz ML, Shea S, Gupta GN, Showalter T, Garant A, Hentz C, Farooq A, Baldea K, Small W, Harkenrider MM. F-SHARP: A Phase I/II Trial of Focal Salvage HDR Brachytherapy for Radiorecurrent Prostate Cancer. Bju International. PMID 37562825 DOI: 10.1111/bju.16150 |
0.322 |
|
| 2023 |
Zaorsky NG, Proudfoot JA, Jia AY, Zuhour R, Vince R, Liu Y, Zhao X, Hu J, Schussler NC, Stevens JL, Bentler S, Cress RD, Doherty JA, Durbin EB, Gershman S, ... ... Davicioni E, et al. Use of the Decipher genomic classifier among men with prostate cancer in the United States. Jnci Cancer Spectrum. PMID 37525535 DOI: 10.1093/jncics/pkad052 |
0.393 |
|
| 2023 |
Chappidi MR, Sjöström M, Greenland NY, Cowan JE, Baskin AS, Shee K, Simko JP, Chan E, Stohr BA, Washington SL, Nguyen HG, Quigley DA, Davicioni E, Feng FY, Carroll PR, et al. Transcriptomic Heterogeneity of Expansile Cribriform and Other Gleason Pattern 4 Prostate Cancer Subtypes. European Urology Oncology. PMID 37474400 DOI: 10.1016/j.euo.2023.06.007 |
0.448 |
|
| 2023 |
Ku AT, Shankavaram U, Trostel SY, Zhang H, Sater HA, Harmon SA, Carrabba NV, Liu Y, Wood BJ, Pinto PA, Choyke PL, Stoyanova R, Davicioni E, Pollack A, Turkbey B, et al. Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence. Medrxiv : the Preprint Server For Health Sciences. PMID 37205576 DOI: 10.1101/2023.05.01.23288883 |
0.452 |
|
| 2023 |
Spratt DE, Liu VYT, Michalski J, Davicioni E, Berlin A, Simko JM, Efstathiou JA, Tran PT, Sandler HM, Hall WA, Thompson DJ, Parliament MB, Dayes IS, Correa RJM, Robertson JM, et al. Genomic classifier performance in intermediate-risk prostate cancer: Results from NRG Oncology/RTOG 0126 randomized phase III trial. International Journal of Radiation Oncology, Biology, Physics. PMID 37137444 DOI: 10.1016/j.ijrobp.2023.04.010 |
0.458 |
|
| 2023 |
Weiner AB, Liu Y, Hakansson A, Zhao X, Proudfoot JA, Ho J, Zhang JH, Li EV, Karnes RJ, Den RB, Kishan AU, Reiter RE, Hamid AA, Ross AE, Tran PT, ... Davicioni E, et al. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. Cancer. PMID 37060201 DOI: 10.1002/cncr.34790 |
0.462 |
|
| 2023 |
Smith CP, Proudfoot JA, Boutros PC, Reiter RE, Valle L, Rettig MB, Nickols NG, Feng FY, Nguyen PL, Nagar H, Spratt DE, Attard G, Weiner A, Weidhaas JB, Calais J, ... ... Davicioni E, et al. Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. European Urology Oncology. PMID 36870853 DOI: 10.1016/j.euo.2023.02.009 |
0.449 |
|
| 2023 |
Attard G, Parry M, Grist E, Mendes L, Dutey-Magni P, Sachdeva A, Brawley C, Murphy L, Proudfoot J, Lall S, Liu Y, Friedrich S, Ismail M, Hoyle A, Ali A, ... ... Davicioni E, et al. Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. Research Square. PMID 36798177 DOI: 10.21203/rs.3.rs-2488586/v1 |
0.474 |
|
| 2023 |
Ramaswamy A, Proudfoot JA, Ross AE, Davicioni E, Schaeffer EM, Hu JC. Prostate Cancer Tumor Volume and Genomic Risk. European Urology Open Science. 48: 90-97. PMID 36743402 DOI: 10.1016/j.euros.2022.12.002 |
0.456 |
|
| 2023 |
Schweizer MT, True L, Gulati R, Zhao Y, Ellis W, Schade G, Montgomery B, Goyal S, Nega K, Hakansson AK, Liu Y, Davicioni E, Pienta K, Nelson PS, Lin D, et al. Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial. The Journal of Urology. 209: 354-363. PMID 36621991 DOI: 10.1097/JU.0000000000003038 |
0.438 |
|
| 2022 |
Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, Efstathiou JA, Simko JP, Pollack A, Dicker AP, Roach M, Rosenthal SA, Zeitzer KL, Mendez LC, Hartford AC, et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: Meta-analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 phase III randomized trials. International Journal of Radiation Oncology, Biology, Physics. PMID 36596347 DOI: 10.1016/j.ijrobp.2022.12.035 |
0.368 |
|
| 2022 |
Spohn SKB, Draulans C, Kishan AU, Spratt D, Ross A, Maurer T, Tilki D, Berlin A, Blanchard P, Collins S, Bronsert P, Chen R, Pra AD, de Meerleer G, Eade T, ... ... Davicioni E, et al. Genomic classifiers in personalized prostate cancer radiotherapy approaches - a systematic review and future perspectives based on international consensus. International Journal of Radiation Oncology, Biology, Physics. PMID 36596346 DOI: 10.1016/j.ijrobp.2022.12.038 |
0.446 |
|
| 2022 |
Swami N, Nguyen T, Ogobuiro I, Abramowitz M, Chipidza F, Davicioni E, Meiyappan K, Pra AD, Nguyen PL, Pollack A, Punnen S, Mahal BA, Alshalalfa M. Distinct Profiles of DNA Repair Activity Define Favorable-risk Prostate Cancer Subtypes With Divergent Outcome. Clinical Genitourinary Cancer. 21: 76-83. PMID 36522269 DOI: 10.1016/j.clgc.2022.11.005 |
0.378 |
|
| 2022 |
Patel N, Hakansson A, Ohtake S, Muraki P, Proudfout JA, Liu Y, Webber L, Ibarra A, Liu VYT, Davicioni E, Chamie K, Pantuck A, Shuch B. Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer. Cancer Medicine. PMID 36397716 DOI: 10.1002/cam4.5399 |
0.331 |
|
| 2022 |
Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, Miller S, Proudfoot JA, Deek MP, Phillips R, Lotan T, Paller CJ, Marshall CH, Markowski M, Dipasquale S, ... ... Davicioni E, et al. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201662. PMID 36367998 DOI: 10.1200/JCO.22.01662 |
0.423 |
|
| 2022 |
Yoshikawa Y, Stopsack KH, Wang XV, Chen YH, Mazzu YZ, Burton F, Chakraborty G, Rajanala SH, Hirani R, Nandakumar S, Lee GM, Frank D, Davicioni E, Liu G, Carducci MA, et al. Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer. Molecular Oncology. PMID 36087093 DOI: 10.1002/1878-0261.13314 |
0.439 |
|
| 2022 |
Awasthi S, Grass GD, Torres-Roca J, Johnstone PAS, Pow-Sang J, Dhillon J, Park J, Rounbehler RJ, Davicioni E, Hakansson A, Liu Y, Fink AK, DeRenzis A, Creed JH, Poch M, et al. Genomic testing in localized prostate cancer can identify subsets of African-Americans with aggressive disease. Journal of the National Cancer Institute. PMID 36053178 DOI: 10.1093/jnci/djac162 |
0.463 |
|
| 2022 |
Chakravarty D, Ratnani P, Huang L, Dovey Z, Sobotka S, Berryhill R, Merisaari H, Al Shaarani M, Rai R, Jambor I, Yadav KK, Mittan S, Parekh S, Kodysh J, Wagaskar V, ... ... Davicioni E, et al. Association between Incidental Pelvic Inflammation and Aggressive Prostate Cancer. Cancers. 14. PMID 35681714 DOI: 10.3390/cancers14112734 |
0.374 |
|
| 2022 |
Lone Z, Benidir T, Rainey M, Nair M, Davicioni E, Gibb EA, Williamson S, Gupta S, Chaim Ornstein M, Tendulkar R, Weight C, Nguyen JK, Klein EA, Mian OY. Transcriptomic Features of Cribriform and Intraductal Carcinoma of the Prostate. European Urology Focus. PMID 35662504 DOI: 10.1016/j.euf.2022.05.005 |
0.403 |
|
| 2022 |
Sutera P, Deek MP, Van der Eecken K, Wyatt AW, Kishan AU, Molitoris JK, Ferris MJ, Siddiqui MM, Rana Z, Mishra MV, Kwok Y, Davicioni E, Spratt DE, Ost P, Feng FY, et al. Genomic biomarkers to guide precision radiotherapy in prostate cancer. The Prostate. S73-S85. PMID 35657158 DOI: 10.1002/pros.24373 |
0.474 |
|
| 2022 |
Kensler KH, Awasthi S, Alshalalfa M, Trock BJ, Freedland SJ, Freeman MR, You S, Mahal BA, Den RB, Dicker AP, Karnes RJ, Klein EA, Lal P, Liu Y, Davicioni E, et al. Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. European Urology Open Science. 40: 19-26. PMID 35638091 DOI: 10.1016/j.euros.2022.03.014 |
0.352 |
|
| 2022 |
Weiner AB, Yu CY, Kini M, Liu Y, Davicioni E, Mitrofanova A, Lotan TL, Schaeffer EM. High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments. Prostate Cancer and Prostatic Diseases. PMID 35568781 DOI: 10.1038/s41391-022-00547-0 |
0.331 |
|
| 2022 |
Qiu X, Boufaied N, Hallal T, Feit A, de Polo A, Luoma AM, Alahmadi W, Larocque J, Zadra G, Xie Y, Gu S, Tang Q, Zhang Y, Syamala S, Seo JH, ... ... Davicioni E, et al. MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets. Nature Communications. 13: 2559. PMID 35562350 DOI: 10.1038/s41467-022-30257-z |
0.406 |
|
| 2022 |
Van den Broeck T, Moris L, Gevaert T, Davicioni E, Boeckx B, Lambrechts D, Helsen C, Handle F, Ghesquiere B, Soenen S, Smeets E, Eerlings R, El Kharraz S, Devlies W, Karnes RJ, et al. Antizyme Inhibitor 1 regulates matrikine expression and enhances the metastatic potential of aggressive primary prostate cancer. Molecular Cancer Research : McR. PMID 35082164 DOI: 10.1158/1541-7786.MCR-21-0388 |
0.425 |
|
| 2022 |
Shahait M, Cheaib JG, Davicioni E, Liu Y, Ghaida IA, Dobbs RW, Alshalalfa M, Lal P, Lee DJ, Lee DI. Does Perioperative Testosterone Predict Post-prostatectomy Genomic Risk Score? The Journal of Urology. 101097JU000000000000. PMID 35050721 DOI: 10.1097/JU.0000000000002440 |
0.435 |
|
| 2021 |
Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, ... ... Davicioni E, et al. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nature Communications. 12: 7349. PMID 34934057 DOI: 10.1038/s41467-021-26901-9 |
0.351 |
|
| 2021 |
Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, Deonarine LD, Cyrta J, Davicioni E, Sboner A, Robinson BD, Chinnaiyan AM, Rubin MA, Barbieri CE, Zhou P. G3BP1 inhibits Cul3 to amplify AR signaling and promote prostate cancer. Nature Communications. 12: 6662. PMID 34795264 DOI: 10.1038/s41467-021-27024-x |
0.371 |
|
| 2021 |
Lotan Y, de Jong J, Liu VYT, Bismar TA, Boorjian SA, Huang HC, Davicioni E, Mian OY, Wright JL, Necchi A, Dall'Era MA, Kaimakliotis HZ, Black PC, Gibb EA, Boormans J. Patients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. The Journal of Urology. 101097JU000000000000. PMID 34643090 DOI: 10.1097/JU.0000000000002261 |
0.306 |
|
| 2021 |
Ramotar M, Chua MLK, Truong H, Hosni A, Pintilie M, Davicioni E, Fleshner NE, Dicker AP, Bristow RG, He HH, van der Kwast T, Den RB, Berlin A. Subpathologies and genomic classifier for treatment individualization of post-prostatectomy radiotherapy. Urologic Oncology. PMID 34538726 DOI: 10.1016/j.urolonc.2021.08.013 |
0.44 |
|
| 2021 |
Grbesa I, Augello MA, Liu D, McNally DR, Gaffney CD, Huang D, Lin K, Ivenitsky D, Goueli R, Robinson BD, Khani F, Deonarine LD, Blattner M, Elemento O, Davicioni E, et al. Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivity. Cell Reports. 36: 109625. PMID 34496233 DOI: 10.1016/j.celrep.2021.109625 |
0.398 |
|
| 2021 |
Weiner AB, Liu Y, McFarlane M, Bawa PS, Li EV, Zhao X, Li Z, Hammoud T, Hazime M, Karnes RJ, Davicioni E, Reichert ZR, Chinnaiyan AM, Lotan TL, Spratt DE, et al. A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 34226663 DOI: 10.1038/s41391-021-00416-2 |
0.42 |
|
| 2021 |
Weiner AB, Liu Y, McFarlane M, Bawa PS, Li EV, Zhao X, Li Z, Hammoud T, Hazime M, Karnes RJ, Davicioni E, Reichert ZR, Chinnaiyan AM, Lotan TL, Spratt DE, et al. A transcriptomic model for homologous recombination deficiency in prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 34226663 DOI: 10.1038/s41391-021-00416-2 |
0.42 |
|
| 2021 |
Rayford W, Beksac AT, Alger J, Alshalalfa M, Ahmed M, Khan I, Falagario UG, Liu Y, Davicioni E, Spratt DE, Schaeffer EM, Feng FY, Mahal B, Nguyen PL, Den RB, et al. Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. Communications Biology. 4: 670. PMID 34083737 DOI: 10.1038/s42003-021-02140-y |
0.383 |
|
| 2021 |
Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, et al. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. Jama Oncology. PMID 34081076 DOI: 10.1001/jamaoncol.2021.1463 |
0.419 |
|
| 2021 |
Liu D, Augello MA, Grbesa I, Prandi D, Liu Y, Shoag JE, Karnes RJ, Trock BJ, Klein EA, Den RB, Demichelis F, Davicioni E, Sboner A, Barbieri CE. Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. The Journal of Clinical Investigation. 131. PMID 33998599 DOI: 10.1172/JCI147878 |
0.416 |
|
| 2021 |
Ding YC, Wu H, Davicioni E, Karnes RJ, Klein EA, Den RB, Steele L, Neuhausen SL. Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. Journal of Translational Genetics and Genomics. 5: 50-61. PMID 33928239 DOI: 10.20517/jtgg.2021.01 |
0.465 |
|
| 2021 |
Alshalalfa M, Abou-Ouf H, Davicioni E, Karnes RJ, Alhajj R, Bismar TA. Expression of ISL1 and its partners in prostate cancer progression and neuroendocrine differentiation. Journal of Cancer Research and Clinical Oncology. PMID 33864110 DOI: 10.1007/s00432-021-03634-2 |
0.443 |
|
| 2021 |
Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan A, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, ... ... Davicioni E, et al. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. European Urology. PMID 33840559 DOI: 10.1016/j.eururo.2021.03.017 |
0.393 |
|
| 2021 |
Feng FY, Huang HC, Spratt DE, Zhao SG, Sandler HM, Simko JP, Davicioni E, Nguyen PL, Pollack A, Efstathiou JA, Dicker AP, Todorovic T, Margrave J, Liu YS, Dabbas B, et al. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. Jama Oncology. PMID 33570548 DOI: 10.1001/jamaoncol.2020.7671 |
0.514 |
|
| 2021 |
Weiner AB, Vidotto T, Liu Y, Mendes AA, Salles DC, Faisal FA, Murali S, McFarlane M, Imada EL, Zhao X, Li Z, Davicioni E, Marchionni L, Chinnaiyan AM, Freedland SJ, et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nature Communications. 12: 935. PMID 33568675 DOI: 10.1038/s41467-021-21245-w |
0.42 |
|
| 2021 |
Yoon J, Kim M, Posadas EM, Freedland SJ, Liu Y, Davicioni E, Den RB, Trock BJ, Karnes RJ, Klein EA, Freeman MR, You S. A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate Cancer and Prostatic Diseases. PMID 33531653 DOI: 10.1038/s41391-021-00325-4 |
0.409 |
|
| 2020 |
Hall WA, Fishbane N, Liu Y, Xu MJ, Davicioni E, Mahal BA, Den RB, Dess RT, Jackson WC, Wong AC, Schaeffer EM, Karnes RJ, Carroll PR, Cooperberg MR, Bismar TA, et al. Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. Jco Precision Oncology. 4: 1228-1238. PMID 35050780 DOI: 10.1200/PO.20.00013 |
0.42 |
|
| 2020 |
Punnen S, Stoyanova R, Kwon D, Reis IM, Soodana-Prakash N, Ritch CR, Nahar B, Gonzalgo ML, Kava B, Liu Y, Arora H, Gaston SM, Castillo Acosta RP, Pra AD, Abramowitz M, ... ... Davicioni E, et al. Heterogeneity in Genomic Risk Assessment From Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of MRI Targeted Biopsy. The Journal of Urology. 101097JU000000000000. PMID 33356482 DOI: 10.1097/JU.0000000000001559 |
0.422 |
|
| 2020 |
Yamoah K, Awasthi S, Mahal BA, Zhao SG, Grass GD, Berglund A, Abraham-Miranda J, Gerke T, Rounbehler RJ, Davicioni E, Liu Y, Park J, Cleveland JL, Pow-Sang JM, Fernandez D, et al. Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer. European Urology. PMID 33303244 DOI: 10.1016/j.eururo.2020.11.038 |
0.409 |
|
| 2020 |
Ben-Salem S, Hu Q, Liu Y, Alshalalfa M, Zhao X, Wang I, Venkadakrishnan VB, Senapati D, Kumari S, Liu D, Sboner A, Barbieri CE, Feng F, Billaud JN, Davicioni E, et al. Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. European Urology Open Science. 22: 34-44. PMID 33299986 DOI: 10.1016/j.euros.2020.10.002 |
0.414 |
|
| 2020 |
Awasthi S, Berglund AE, Abraham-Miranda J, Rounbehler RJ, Kensler KH, Serna AN, Vidal AC, You S, Freeman MR, Davicioni E, Liu Y, Karnes JR, Klein EA, Den RB, Trock BJ, et al. Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33037017 DOI: 10.1158/1078-0432.CCR-20-2925 |
0.384 |
|
| 2020 |
Chipidza FE, Alshalalfa M, Mahal BA, Karnes RJ, Liu Y, Davicioni E, Martin NE, Mouw KW, Feng FY, Nguyen PL, Muralidhar V. Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. Clinical Genitourinary Cancer. PMID 32896505 DOI: 10.1016/J.Clgc.2020.08.004 |
0.449 |
|
| 2020 |
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, et al. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. PMID 32895534 DOI: 10.1038/S41586-020-2678-X |
0.434 |
|
| 2020 |
Ferrari MG, Ganaie AA, Shabenah A, Mansini AP, Wang L, Murugan P, Davicioni E, Wang J, Deng Y, Hoeppner LH, Warlick CA, Konety BR, Saleem M. Identifying and treating ROBO1 /DOCK1 prostate cancer: An aggressive cancer subtype prevalent in African American patients. The Prostate. PMID 32687658 DOI: 10.1002/Pros.24018 |
0.528 |
|
| 2020 |
Bahler CD, Johnson MM, Davicioni E, Zhang J, Cheng L, Green MA, Koch MO. Predictors of prostate specific membrane antigen (PSMA/FOLH1) expression in a genomic database. Urology. PMID 32619596 DOI: 10.1016/J.Urology.2020.06.025 |
0.421 |
|
| 2020 |
Tabrizi S, Alshalalfa M, Mahal BA, Davicioni E, Liu Y, Mouw KW, Feng F, Nguyen PL, Muralidhar V. Doublecortin expression in prostate adenocarcinoma and neuroendocrine tumors. International Journal of Radiation Oncology, Biology, Physics. PMID 32585335 DOI: 10.1016/J.Ijrobp.2020.06.024 |
0.539 |
|
| 2020 |
Weiner AB, Faisal FA, Davicioni E, Karnes RJ, Griend DJV, Lotan TL, Schaeffer EM. Somatic HOXB13 Expression Correlates with Metastatic Progression in Men with Localized Prostate Cancer Following Radical Prostatectomy. European Urology Oncology. PMID 32540218 DOI: 10.1016/J.Euo.2020.05.001 |
0.537 |
|
| 2020 |
Kishan AU, Romero T, Alshalalfa M, Liu Y, Tran PT, Nickols NG, Ye H, Sajed D, Rettig MB, Reiter RE, Garraway IP, Spratt DE, Freedland SJ, Zhao X, Li Z, ... ... Davicioni E, et al. Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. European Urology. PMID 32461072 DOI: 10.1016/J.Eururo.2020.05.009 |
0.492 |
|
| 2020 |
Necchi A, Raggi D, Giannatempo P, Marandino L, Farè E, Gallina A, Colecchia M, Lucianò R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Dittamore R, Liu Y, ... Davicioni E, et al. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. European Urology Oncology. PMID 32417369 DOI: 10.1016/J.Euo.2020.04.005 |
0.399 |
|
| 2020 |
Tosoian JJ, Birer SR, Jeffrey Karnes R, Zhang J, Davicioni E, Klein EE, Freedland SJ, Weinmann S, Trock BJ, Dess RT, Zhao SG, Jackson WC, Yamoah K, Pra AD, Mahal BA, et al. Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. Prostate Cancer and Prostatic Diseases. PMID 32231245 DOI: 10.1038/S41391-020-0226-2 |
0.584 |
|
| 2020 |
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E, Karnes J, Den RB, Liu Y, Davicioni E, Barbieri CE. Prognostic value of the SPOP mutant genomic subclass in prostate cancer. Urologic Oncology. PMID 32192889 DOI: 10.1016/J.Urolonc.2020.02.011 |
0.515 |
|
| 2020 |
Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, Marandino L, Colecchia M, Lucianò R, Bianchi M, Colombo R, Salonia A, Gandaglia G, Fossati N, Bandini M, ... ... Davicioni E, et al. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. European Urology. PMID 32165065 DOI: 10.1016/J.Eururo.2020.02.028 |
0.368 |
|
| 2020 |
Goldberg H, Spratt D, Chandrasekar T, Klaassen Z, Wallis CJD, Santiago-Jimenez M, Fishbane N, Davicioni E, Noorani R, Ahmad AE, Herrera Cáceres JO, Alibhai S, Berlin A, Fleshner NE. Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease. European Urology Focus. PMID 32156491 DOI: 10.1016/J.Euf.2020.02.008 |
0.558 |
|
| 2020 |
de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging. The Journal of Urology. 101097JU000000000000. PMID 32074006 DOI: 10.1097/Ju.0000000000000798 |
0.365 |
|
| 2020 |
Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, Spratt DE, Feng FY, et al. Genomic and clinical characterization of stromal infiltration markers in prostate cancer. Cancer. PMID 31905251 DOI: 10.1002/Cncr.32688 |
0.572 |
|
| 2020 |
King MT, Wise DR, Scala LM, Mariados NM, Whitbeck A, Pomerantz M, Bober S, Davicioni E, Bubley G, Nguyen PL. INTREPId (INTermediate Risk Erection PreservatIon Trial): A randomized trial of radiation therapy and darolutamide for prostate cancer. Journal of Clinical Oncology. 38: TPS384-TPS384. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps384 |
0.483 |
|
| 2020 |
Necchi A, Meeks JJ, Bandini M, Fall LA, Raggi D, Briganti A, Farè E, Giannatempo P, McLaughlin KA, Das A, Marandino L, Gallina A, Salonia A, Gandaglia G, Fossati N, ... ... Davicioni E, et al. Development of a composite biomarker-based calculator to predict the probability of pathologic complete response (pT0) after neoadjuvant pembrolizumab (pembro) in muscle invasive bladder cancer (MIBC). Journal of Clinical Oncology. 38: 539-539. DOI: 10.1200/Jco.2020.38.6_Suppl.539 |
0.363 |
|
| 2020 |
Necchi A, Raggi D, Briganti A, Farè E, Giannatempo P, Marandino L, Bianchi M, Gallina A, Salonia A, Gandaglia G, Fossati N, Capitanio U, Montorsi F, Boormans JL, Liu Y, ... ... Davicioni E, et al. Association of an immune gene signature with pathologic response and outcome after neoadjuvant pembrolizumab (pembro), compared to neoadjuvant chemotherapy (NAC), in muscle-invasive bladder cancer (MIBC). Journal of Clinical Oncology. 38: 533-533. DOI: 10.1200/Jco.2020.38.6_Suppl.533 |
0.328 |
|
| 2020 |
Gupta S, Sonpavde G, Weight CJ, McGregor BA, Gupta S, Maughan BL, Wei XX, Gibb E, Thyagarajan B, Einstein DJ, Dechet CB, Lowrance WT, Murugan PJ, Kilbridge KL, Agarwal N, ... Davicioni E, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. Journal of Clinical Oncology. 38: 439-439. DOI: 10.1200/Jco.2020.38.6_Suppl.439 |
0.391 |
|
| 2020 |
Ganguly S, Balyimez A, Lone Z, Hardaway A, Patel M, Davicioni E, Ornstein MC, Garcia JA, Stephans KL, Ciezki JP, Tendulkar RD, Klein EA, Sharifi N, Mian OY. Tumor cell intrinsic androgen biosynthesis by 3β-hydroxy steroid dehydrogenase (HSD3B1) to modulate radiosensitivity in prostate cancer cells. Journal of Clinical Oncology. 38: 349-349. DOI: 10.1200/Jco.2020.38.6_Suppl.349 |
0.399 |
|
| 2020 |
Shahait M, Alshalalfa M, Schaeffer EM, Huang H, Cronican A, Nguyen PL, el-Fahmawi A, Lal P, Davicioni E, Lee DI. Head-to-head comparison between decipher and prolaris tests: Two commercially available post-prostatectomy genomic tests. Journal of Clinical Oncology. 38: 348-348. DOI: 10.1200/Jco.2020.38.6_Suppl.348 |
0.342 |
|
| 2020 |
Muralidhar V, Alshalalfa M, Spratt DE, Liu Y, Karnes RJ, Schaeffer EM, Davicioni E, Feng FY, Klein EA, Tosoian JJ, Berlin A, Den RB, Nguyen PL. Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design. Journal of Clinical Oncology. 38: 337-337. DOI: 10.1200/Jco.2020.38.6_Suppl.337 |
0.483 |
|
| 2020 |
Chu C, Alshalalfa M, Sjöström M, Zhao S, Herlemann A, Chou J, Mahal BAV, Kishan AU, Spratt DE, Karnes J, Small EJ, Wong AC, Porten SP, Hope T, Davicioni E, et al. Characterization of PSMA and 18F-fluciclovine transporter gene expression in localized prostate cancer. Journal of Clinical Oncology. 38: 295-295. DOI: 10.1200/Jco.2020.38.6_Suppl.295 |
0.476 |
|
| 2020 |
Feng FY, Sandler HM, Huang H, Simko J, Davicioni E, Nguyen PL, Efstathiou JA, Dicker AP, Dignam JJ, Seiferheld W, Lukka H, Bahary J, Pisansky TM, Hall WA, Shah AI, et al. Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial. Journal of Clinical Oncology. 38: 276-276. DOI: 10.1200/Jco.2020.38.6_Suppl.276 |
0.59 |
|
| 2020 |
Hamid A, Wang XV, Chen Y, Feng FY, Den RB, Attard G, Van Allen EM, Huang H, Karns A, Dittamore R, Davicioni E, Liu G, DiPaola RS, Carducci MA, Sweeney C. Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED. Journal of Clinical Oncology. 38: 162-162. DOI: 10.1200/Jco.2020.38.6_Suppl.162 |
0.467 |
|
| 2020 |
Grist E, Parry M, Mendes L, Lall S, Kudahetti SC, Vidal SS, Atako NB, Anjum M, Ishaq S, Todorovic T, Huang H, Waugh D, Sweeney C, Clarke N, James ND, ... ... Davicioni E, et al. Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis. Journal of Clinical Oncology. 38: 153-153. DOI: 10.1200/Jco.2020.38.6_Suppl.153 |
0.522 |
|
| 2020 |
Yoshikawa Y, Wang XV, Chen Y, Mazzu YZ, Chakraborty G, Jehane LE, Rajanala SH, Hirani R, Nandakumar S, Stopsack KH, Lee GM, Davicioni E, Liu G, DiPaola RS, Carducci MA, et al. The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer. Journal of Clinical Oncology. 38: 149-149. DOI: 10.1200/Jco.2020.38.6_Suppl.149 |
0.538 |
|
| 2020 |
Feng FY, Thomas S, Aguilar-Bonavides C, Gormley M, Agarwal N, Attard G, Wyatt AW, Davicioni E, Ricci DS, Lopez-Gitlitz A, Larsen JS, Chowdhury S, Chi KN. Molecular determinants of outcome for metastatic castration-sensitive prostate cancer (mCSPC) with addition of apalutamide (APA) or placebo (PBO) to androgen deprivation therapy (ADT) in TITAN. Journal of Clinical Oncology. 38: 5535-5535. DOI: 10.1200/Jco.2020.38.15_Suppl.5535 |
0.456 |
|
| 2020 |
Saad F, Graff JN, Hadaschik BA, Oudard S, Mainwaring PN, Bhaumik A, Gormley M, Londhe A, Thomas S, Lopez-Gitlitz A, Mundle S, Davicioni E, Small EJ, Smith MR, Feng FY. Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN. Journal of Clinical Oncology. 38: 5521-5521. DOI: 10.1200/Jco.2020.38.15_Suppl.5521 |
0.514 |
|
| 2020 |
Jong JJd, Liu Y, Seiler R, Robertson AG, Heijden MSvd, Wright JL, Douglas J, Dall'Era M, Crabb SJ, Rhijn BWGv, Kessel KEMv, Davicioni E, Lotan Y, Zwarthoff EC, Black PC, et al. Abstract B07: A long noncoding RNA-based genomic classifier identifies a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Bladder19-B07 |
0.434 |
|
| 2020 |
Yamoah K, Awasthi S, Mahal B, Zhao SG, Abraham-Miranda J, Gerke TA, Davicioni E, Rounbehler RJ, Berglund AE, Grass DG, Park JY, Pow-Sang JM, Fernandez D, Jain RK, Schaeffer EM, et al. Abstract 3520: Immunogenomic landscape of grade group 5 prostate cancer predicts risk of lethal outcomes and may inform treatment response Epidemiology. 80: 3520-3520. DOI: 10.1158/1538-7445.Am2020-3520 |
0.555 |
|
| 2020 |
Kensler KH, Alshalalfa M, Mahal BA, Liu Y, Davicioni E, Awasthi S, Yamoah K, Rebbeck TR. Abstract 3509: Racial variation in molecularly-defined prostate cancer subtypes Epidemiology. 80: 3509-3509. DOI: 10.1158/1538-7445.Am2020-3509 |
0.545 |
|
| 2020 |
Ganguly S, Balyimez A, lone Z, Hardaway A, Patel M, Davicioni E, Tendulkar R, Klein E, Sharifi N, Mian O. Abstract 2082: Extragonadal and regional androgen biosynthesis associated with a common steroidogenic enzyme polymorphism promotes radioresistance in prostate cancer Epidemiology. 80: 2082-2082. DOI: 10.1158/1538-7445.Am2020-2082 |
0.435 |
|
| 2020 |
Chu* C, Alshalalfa M, Sjostrom M, Zhao S, Herlemann A, Chou J, Mahal B, Kishan A, Spratt D, Cooperberg M, Karnes J, Small E, Nguyen P, Wong A, Hope T, ... ... Davicioni E, et al. PD54-02 CHARACTERIZATION OF PSMA AND 18F-FLUCICLOVINE TRANSPORTER GENE EXPRESSION IN LOCALIZED PROSTATE CANCER The Journal of Urology. 203: e1103-e1104. DOI: 10.1097/Ju.0000000000000956.02 |
0.433 |
|
| 2020 |
Necchi* A, Raggi D, Briganti A, Farè E, Giannatempo P, Marandino L, Gallina A, Bianchi M, Salonia A, Gandaglia G, Fossati N, Capitanio U, Montorsi F, Boormans J, Liu Y, ... ... Davicioni E, et al. MP55-09 ASSOCIATION OF AN IMMUNE-GENE SIGNATURE WITH PATHOLOGIC RESPONSE AND OUTCOME AFTER NEOADJUVANT PEMBROLIZUMAB (PEMBRO), COMPARED TO NEOADJUVANT CHEMOTHERAPY (NAC), IN MUSCLE-INVASIVE BLADDER CANCER (MIBC) The Journal of Urology. 203: e841. DOI: 10.1097/Ju.0000000000000924.09 |
0.357 |
|
| 2019 |
Rai R, Yadav SS, Pan H, Khan I, O'Connor J, Alshalalfa M, Davicioni E, Taioli E, Elemento O, Tewari AK, Yadav KK. Epigenetic analysis identifies factors driving racial disparity in prostate cancer. Cancer Reports (Hoboken, N.J.). 2: e1153. PMID 32721098 DOI: 10.1002/cnr2.1153 |
0.399 |
|
| 2019 |
Howard LE, Zhang J, Fishbane N, Hoedt AM, Klaassen Z, Spratt DE, Vidal AC, Lin D, Hitchins MP, You S, Freeman MR, Yamoah K, Davicioni E, Freedland SJ. Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate Cancer and Prostatic Diseases. PMID 31844180 DOI: 10.1038/S41391-019-0197-3 |
0.508 |
|
| 2019 |
Grivas P, Bismar TA, Alva AS, Huang HC, Liu Y, Seiler R, Alimohamed N, Cheng L, Hyndman ME, Dabbas B, Black PC, Davicioni E, Wright JL, Ornstein MC, Mian OY, et al. Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urologic Oncology. PMID 31812633 DOI: 10.1016/J.Urolonc.2019.11.004 |
0.365 |
|
| 2019 |
Gore JL, du Plessis M, Zhang J, Dai D, Thompson DJS, Karsh L, Lane B, Franks M, Chen DYT, Bianco FJ, Brown G, Clark W, Kibel AS, Kim H, Lowrance W, ... ... Davicioni E, et al. Clinical Utility of a Genomic Classifier in Men Undergoing Radical Prostatectomy: The PRO-IMPACT Trial. Practical Radiation Oncology. PMID 31761540 DOI: 10.1016/J.Prro.2019.09.016 |
0.527 |
|
| 2019 |
Marascio J, Spratt DE, Zhang J, Trabulsi EJ, Le T, Sedzorme WS, Beeler WH, Davicioni E, Dabbas B, Lin DW, Gore JL, Bloom M, Mann M, Mark JR, Calvaresi A, et al. Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy. Prostate Cancer and Prostatic Diseases. PMID 31719663 DOI: 10.1038/S41391-019-0185-7 |
0.531 |
|
| 2019 |
de Jong JJ, Liu Y, Robertson AG, Seiler R, Groeneveld CS, van der Heijden MS, Wright JL, Douglas J, Dall'Era M, Crabb SJ, van Rhijn BWG, van Kessel KEM, Davicioni E, Castro MAA, Lotan Y, et al. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. Genome Medicine. 11: 60. PMID 31619281 DOI: 10.1186/S13073-019-0669-Z |
0.359 |
|
| 2019 |
Sjöström M, Chang SL, Fishbane N, Davicioni E, Zhao SG, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P. Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900761. PMID 31618132 DOI: 10.1200/Jco.19.00761 |
0.309 |
|
| 2019 |
Genitsch V, Kollár A, Vandekerkhove G, Blarer J, Furrer M, Annala M, Herberts C, Pycha A, de Jong JJ, Liu Y, Krentel F, Davicioni E, Gibb EA, Kruithof-de Julio M, Wyatt AW, et al. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urologic Oncology. PMID 31585777 DOI: 10.1016/J.Urolonc.2019.09.025 |
0.389 |
|
| 2019 |
Sjöström M, Chang SL, Fishbane N, Davicioni E, Hartman L, Holmberg E, Feng FY, Speers C, Pierce LJ, Malmström P, Fernö M, Karlsson P. ---Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31558478 DOI: 10.1158/1078-0432.Ccr-19-1038 |
0.347 |
|
| 2019 |
Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, Ebot EM, Creech AL, Giunchi F, Fiorentino M, Elfandy H, Syamala S, Karoly ED, Alshalalfa M, Erho N, ... ... Davicioni E, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nature Communications. 10: 4358. PMID 31554818 DOI: 10.1038/S41467-019-12298-Z |
0.486 |
|
| 2019 |
Spratt DE, Alshalalfa M, Fishbane N, Weiner AB, Mehra R, Mahal BA, Lehrer J, Liu Y, Zhao SG, Speers C, Morgan TM, Dicker AP, Freedland SJ, Karnes RJ, Weinmann S, ... Davicioni E, et al. Transcriptomic heterogeneity of androgen receptor (AR) activity defines a low AR-active subclass in treatment naïve primary prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31515456 DOI: 10.1158/1078-0432.Ccr-19-1587 |
0.516 |
|
| 2019 |
Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, et al. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer and Prostatic Diseases. PMID 31455846 DOI: 10.1038/S41391-019-0167-9 |
0.502 |
|
| 2019 |
Ramnarine VR, Kobelev M, Gibb EA, Nouri M, Lin D, Wang Y, Buttyan R, Davicioni E, Zoubeidi A, Collins CC. The evolution of long noncoding RNA acceptance in prostate cancer initiation and progression, and its clinical utility in disease management. European Urology. PMID 31445843 DOI: 10.1016/J.Eururo.2019.07.040 |
0.512 |
|
| 2019 |
Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, et al. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. European Urology Oncology. PMID 31411984 DOI: 10.1016/J.Euo.2018.11.002 |
0.585 |
|
| 2019 |
Van den Broeck T, Moris L, Gevaert T, Tosco L, Smeets E, Fishbane N, Liu Y, Helsen C, Margrave J, Buerki C, Davicioni E, Van Poppel H, Everaerts W, Weinmann S, Den R, et al. Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery. European Urology Oncology. PMID 31411980 DOI: 10.1016/J.Euo.2018.12.007 |
0.561 |
|
| 2019 |
Cheng A, Zhao S, FitzGerald LM, Wright JL, Kolb S, Karnes RJ, Jenkins RB, Davicioni E, Ostrander EA, Feng Z, Fan JB, Dai JY, Stanford JL. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. The Prostate. PMID 31376183 DOI: 10.1002/Pros.23882 |
0.561 |
|
| 2019 |
Muralidhar V, Zhang J, Wang Q, Mahal BA, Butler SS, Spratt DE, Davicioni E, Sartor O, Feng FY, Mouw KW, Nguyen PL. Genomic validation of three-tiered clinical sub-classification of high-risk prostate cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 31271825 DOI: 10.1016/J.Ijrobp.2019.06.2510 |
0.575 |
|
| 2019 |
Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. PMID 31243370 DOI: 10.1038/S41586-019-1318-9 |
0.37 |
|
| 2019 |
Narayan VM, Gupta S, Davicioni E, Murugan P, Gibb EA, Konety B. Genomic Analysis and Treatment Response of a Bladder Urothelial Carcinoma With Sarcomatoid Variant Histology. Clinical Genitourinary Cancer. PMID 31239241 DOI: 10.1016/J.Clgc.2019.05.019 |
0.319 |
|
| 2019 |
Boufaied N, Takhar M, Nash C, Erho N, Bismar TA, Davicioni E, Thomson AA. Development of a predictive model for stromal content in prostate cancer samples to improve signature performance. The Journal of Pathology. PMID 31206668 DOI: 10.1002/Path.5315 |
0.556 |
|
| 2019 |
Alshalalfa M, Nguyen PL, Beltran H, Chen WS, Davicioni E, Zhao SG, Rebbeck TR, Schaeffer EM, Lotan TL, Feng FY, Mahal BA. Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. European Urology Oncology. PMID 31164324 DOI: 10.1016/J.Euo.2019.05.001 |
0.553 |
|
| 2019 |
Alshalalfa M, Liu Y, Wyatt AW, Gibb EA, Tsai HK, Erho N, Lehrer J, Takhar M, Ramnarine VR, Collins CC, Den RB, Schaeffer EM, Davicioni E, Lotan TL, Bismar TA. Characterization of Transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. International Journal of Cancer. PMID 31125117 DOI: 10.1002/Ijc.32430 |
0.555 |
|
| 2019 |
Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan TL, Huang J, Davicioni E, An SS, Riddle RC, Thorek DL, Garraway IP, et al. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research. PMID 31123087 DOI: 10.1158/0008-5472.Can-18-2931 |
0.354 |
|
| 2019 |
Echevarria MI, Awasthi S, Cheng CH, Berglund AE, Rounbehler RJ, Gerke TA, Takhar M, Davicioni E, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Den RB, Cleveland JL, Park JY, et al. African American Specific Gene Panel Predictive of Poor Prostate Cancer Outcome. The Journal of Urology. 101097JU000000000000. PMID 31107158 DOI: 10.1097/Ju.0000000000000193 |
0.485 |
|
| 2019 |
Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. European Urology. PMID 31092337 DOI: 10.1016/J.Eururo.2019.04.036 |
0.326 |
|
| 2019 |
Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31010837 DOI: 10.1158/1078-0432.Ccr-19-0404 |
0.399 |
|
| 2019 |
Hectors SJ, Cherny M, Yadav KK, Beksaç AT, Thulasidass H, Lewis S, Davicioni E, Wang P, Tewari AK, Taouli B. Radiomics features measured with multiparametric MRI predict prostate cancer aggressiveness. The Journal of Urology. 101097JU000000000000. PMID 30958743 DOI: 10.1097/Ju.0000000000000272 |
0.517 |
|
| 2019 |
Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright JL, Dall'Era M, Douglas J, Boormans JL, van der Heijden MS, Wu CL, van Rhijn BW, et al. Molecular characterization of neuroendocrine-like bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30952638 DOI: 10.1158/1078-0432.Ccr-18-3558 |
0.417 |
|
| 2019 |
Shoag J, Liu D, Ma X, Oromendia C, Angulo C, Liu S, Liu Y, Davicioni E, Barbieri C. MP68-12 IMPACT OF SPOP MUTATION ON PROSTATE CANCER PROGNOSIS. The Journal of Urology. 201: e979-e980. PMID 30950719 DOI: 10.1097/01.Ju.0000557027.87083.D3 |
0.516 |
|
| 2019 |
Purysko AS, Magi-Galluzzi C, Mian OY, Sittenfeld S, Davicioni E, du Plessis M, Buerki C, Bullen J, Li L, Madabhushi A, Stephenson A, Klein EA. Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. European Radiology. PMID 30847589 DOI: 10.1007/S00330-019-06114-X |
0.545 |
|
| 2019 |
Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, Ren S, Collins CC. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. Bmc Genomics. 20: 146. PMID 30777011 DOI: 10.1186/S12864-019-5457-Z |
0.535 |
|
| 2019 |
Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, ... ... Davicioni E, et al. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. PMID 30773341 DOI: 10.1016/J.Ccell.2019.01.008 |
0.522 |
|
| 2019 |
Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-sparing Trimodality Therapy for Muscle-invasive Bladder Cancer. European Urology. PMID 30712971 DOI: 10.1016/J.Eururo.2019.01.011 |
0.358 |
|
| 2019 |
Mahal BA, Alshalalfa M, Spratt DE, Davicioni E, Zhao SG, Feng FY, Rebbeck TR, Nguyen PL, Huang FW. Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. European Urology. PMID 30683576 DOI: 10.1016/J.Eururo.2019.01.010 |
0.536 |
|
| 2019 |
Freedland SJ, Du Plessis M, Zhang J, Howard L, de Hoedt A, Davicioni E. A genomic classifier shows improved prediction of oncologic outcomes in African-American men treated with radical prostatectomy. Journal of Clinical Oncology. 37: 8-8. DOI: 10.1200/Jco.2019.37.7_Suppl.8 |
0.419 |
|
| 2019 |
Kishan AU, Romero T, Elashoff D, Grogan T, Rettig M, Reiter RE, Tran PT, Nguyen PL, Nickols NG, Davicioni E, Spratt DE, Feng FY, Weidhaas JB. Genomic biomarkers to predict outcome in Gleason Score 9-10 disease. Journal of Clinical Oncology. 37: 44-44. DOI: 10.1200/Jco.2019.37.7_Suppl.44 |
0.478 |
|
| 2019 |
Feng FY, Thomas S, Gormley M, Lopez-Gitlitz A, Yu MK, Cheng S, Ricci DS, Rooney OB, Mainwaring PN, Olmos D, Saad F, Chowdhury S, Hadaschik BA, Fishbane N, Davicioni E, et al. Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. Journal of Clinical Oncology. 37: 42-42. DOI: 10.1200/Jco.2019.37.7_Suppl.42 |
0.445 |
|
| 2019 |
Goldberg H, Herrera Cáceres JO, Santiago-Jimenez M, Fishbane N, Davicioni E, Klaassen ZWA, Chandrasekar T, Wallis C, Woon TS, Hamilton RJ, Kulkarni GS, Berlin A, Fleshner NE. Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of decipher and PAM50 TESTS among different age groups. Journal of Clinical Oncology. 37: 38-38. DOI: 10.1200/Jco.2019.37.7_Suppl.38 |
0.462 |
|
| 2019 |
Muralidhar V, Zhang J, Spratt DE, Feng FY, Davicioni E, Yousefi K, Wang N, Choeurng V, Nguyen PL. Genomic validation of three-tiered sub-classification of high-risk prostate cancer. Journal of Clinical Oncology. 37: 17-17. DOI: 10.1200/jco.2019.37.7_suppl.17 |
0.424 |
|
| 2019 |
Gupta S, Weight CJ, Agarwal N, Gupta S, Konety B, Gibb E, Davicioni E, Thyagarajan B, Sonpavde G. Abstract A008: Neoadjuvant nivolumab, gemcitabine and cisplatin in muscle-invasive bladder cancer: Study update Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A008 |
0.418 |
|
| 2019 |
Feng F, Thomas S, Gormley M, Lopez-Gitlitz A, Yu MK, Cheng S, Ricci DS, Rooney B, Mainwaring PN, Olmos D, Saad F, Chowdhury S, Hadaschik B, Fishbane N, Davicioni E, et al. Abstract CT129: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct129 |
0.514 |
|
| 2019 |
Faisal* F, Alshalalfa M, Davicioni E, Karnes RJ, Isaacs W, Lotan T, Schaeffer E. MP68-10 HOXB13 EXPRESSION AND ITS ROLE IN PROSTATE CANCER PROGRESSION AND NEUROENDOCRINE DIFFERENTIATION Journal of Urology. 201. DOI: 10.1097/01.Ju.0000557025.09954.39 |
0.504 |
|
| 2019 |
Morgan T, Okoth L, Feng F, Johnson A, Lane B, Linsell S, Ghani K, Montie J, Fishbane N, Marti T, Plessis Md, Mehra R, Davicioni E, Maatman T, Wojno K, et al. Mp54-12 Prospective Randomized Trial Of Gene Exression Classifier Utilty In Men At High Risk Of Recurrence Following Radical Prostatectomy The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556683.01213.Ea |
0.432 |
|
| 2019 |
Freedland* S, du Plessis M, Zhang J, Howard L, De Hoedt A, Davicioni E. PD40-04 A GENOMIC CLASSIFIER SHOWS IMPROVED PREDICTION OF ONCOLOGIC OUTCOMES IN AFRICAN-AMERICAN MEN TREATED WITH RADICAL PROSTATECTOMY Journal of Urology. 201. DOI: 10.1097/01.Ju.0000556415.00894.25 |
0.365 |
|
| 2019 |
Purysko* A, Magi-Galluzzi C, Mian O, Davicioni E, Plessis Md, Buerki C, Bullen J, Li L, Madabhushi A, Stephenson A, Klein E. MP28-04 CORRELATION BETWEEN MRI PHENOTYPES AND A GENOMIC CLASSIFIER OF PROSTATE CANCER Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555709.00017.09 |
0.524 |
|
| 2019 |
Goldberg* H, Herrera Cáceres JO, Santiago-Jimenez M, Fishbaen N, Davicioni E, Klaassen Z, Chandrasekar T, Wallis C, Woon D, Hamilton R, Kulkarni G, Berlin A, Fleshner N. MP28-03 DO ELDERLY MEN (>75) HARBOR MORE AGGRESSIVE PROSTATE CANCER? COMPARISON OF DECIPHER AND PAM50 TESTS AMONG DIFFERENT AGE GROUPS Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555708.92392.E3 |
0.48 |
|
| 2019 |
Mahal* B, Alshalalfa M, Zhao S, Chen W, Davicioni E, Feng F, Nguyen P. PD11-04 GENOMIC EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF STROMAL MICROENVIRONMENT IN PRIMARY PROSTATE CANCER Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555360.67170.96 |
0.542 |
|
| 2019 |
Saad* F, Thomas S, Feng FY, Gormley M, Lopez-Gitlitz A, Yu MK, Cheng S, Ricci DS, Rooney OB, Mainwaring PN, Olmos D, Chowdhury S, Hadaschik BA, Fishbane N, Davicioni E, et al. PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555359.59547.3E |
0.509 |
|
| 2019 |
Genitsch V, Kollár A, Blarer J, Vandekerkhove G, Furrer M, Krentel A, Gibb E, Davicioni E, Wyatt A, Seiler R. Molecular decoding of sarcomatoid variant of muscle-invasive bladder cancer might reveal treatment strategies European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)31044-9 |
0.348 |
|
| 2019 |
Lotan* Y, Boorjian S, Zhang J, Bivalacqua T, Lerner S, Porten S, Wheeler T, Hutchinson R, Francis F, Plessis Md, Davicioni E, Svatek R, Black P, Gibb E. MP26-15 MOLECULAR SUBTYPING REVEALS LUMINAL BLADDER TUMORS HAVE LOWER RATES OF PATHOLOGICAL UPSTAGING AT RADICAL CYSTECTOMY Journal of Urology. 201. DOI: 10.1016/S1569-9056(19)30467-1 |
0.371 |
|
| 2019 |
Sowalsky A, Turkbey B, Trostel S, Shankavaram U, Carrabba N, Sater H, Lake R, Rowe L, Cooley-Zgela T, Schott E, Zhang H, Pinto P, Wood B, Liu S, Davicioni E, et al. Integrated Radiogenomic Subtyping and Treatment Response of Intermediate and High Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 105: S77. DOI: 10.1016/j.ijrobp.2019.06.537 |
0.421 |
|
| 2019 |
Chen W, Mahal B, Alshalalfa M, Zhao S, Beltran H, Davicioni E, Karnes R, Ku S, Lotan T, Rebbeck T, Schaeffer E, Feng F, Nguyen P. Associations of Stromal Infiltration with Prognosis and Response to Postoperative Radiotherapy in Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 105: S39. DOI: 10.1016/j.ijrobp.2019.06.458 |
0.437 |
|
| 2019 |
Kishan A, Romero T, Grogan T, Alshalalfa M, Boutros P, Rettig M, Reiter R, Tran P, Nguyen P, Nickols N, Davicioni E, Spratt D, Feng F, Den R, Freedland S, et al. Transcriptomic Heterogeneity in Pathological Grade Group 5 Prostate Cancer: Implications for Biomarker Discovery International Journal of Radiation Oncology*Biology*Physics. 105: E286-E287. DOI: 10.1016/J.Ijrobp.2019.06.1823 |
0.434 |
|
| 2019 |
Zavala-Romero O, Pollack A, Kwon D, Breto A, Davicioni E, Abramowitz M, Pra AD, Punnen S, Stoyanova R. Clinical-genomic Risk Group Classification of Suspicions Lesions on Prostate mpMRI International Journal of Radiation Oncology*Biology*Physics. 105: S135-S136. DOI: 10.1016/j.ijrobp.2019.06.126 |
0.368 |
|
| 2018 |
Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, ... Davicioni E, et al. Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. Jco Precision Oncology. 2018. PMID 30761387 DOI: 10.1200/PO.18.00036 |
0.47 |
|
| 2018 |
Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, et al. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30573691 DOI: 10.1158/1078-0432.Ccr-18-3121 |
0.349 |
|
| 2018 |
Beksac AT, Cumarasamy S, Falagario U, Xu P, Takhar M, Alshalalfa M, Gupta A, Prasad S, Martini A, Thulasidass H, Rai R, Berger M, Hectors S, Jordan J, Davicioni E, et al. Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level. The Journal of Urology. 200: 1241-1249. PMID 30563651 DOI: 10.1016/J.Juro.2018.06.041 |
0.467 |
|
| 2018 |
Kim HL, Li P, Huang HC, Deheshi S, Marti T, Knudsen B, Abou-Ouf H, Alam R, Lotan TL, Lam LLC, du Plessis M, Davicioni E, Fleshner N, Lane BR, Ross AE, et al. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases. PMID 30542054 DOI: 10.1038/S41391-018-0101-6 |
0.585 |
|
| 2018 |
Gerke T, Beltran H, Wang X, Lee GM, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross AE, Börnigen D, Huttenhower C, Mucci LA, Trock BJ, Sweeney CJ. Low Tristetraprolin Expression is Associated with Lethal Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30420441 DOI: 10.1158/1055-9965.Epi-18-0667 |
0.521 |
|
| 2018 |
Berglund AE, Rounbehler RJ, Gerke T, Awasthi S, Cheng CH, Takhar M, Davicioni E, Alshalalfa M, Erho N, Klein EA, Freedland SJ, Ross AE, Schaeffer EM, Trock BJ, Den RB, et al. Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 30367117 DOI: 10.1038/S41391-018-0103-4 |
0.433 |
|
| 2018 |
Zhao SG, Lehrer J, Chang SL, Das R, Erho N, Liu Y, Sjöström M, Den RB, Freedland SJ, Klein EA, Karnes RJ, Schaeffer EM, Xu M, Speers C, Nguyen PL, ... ... Davicioni E, et al. The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target. Journal of the National Cancer Institute. PMID 30321406 DOI: 10.1093/Jnci/Djy141 |
0.485 |
|
| 2018 |
Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam HM, Van Kessel KE, Voskuilen CS, Winters B, Erho NG, Takhar MM, Douglas J, Vakar-Lopez F, Crabb SJ, van Rhijn BWG, Fransen van de Putte EE, ... ... Davicioni E, et al. Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30224344 DOI: 10.1158/1078-0432.Ccr-18-1106 |
0.386 |
|
| 2018 |
Berlin A, Murgic J, Hosni A, Pintilie M, Salcedo A, Fraser M, Kamel-Reid S, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, van der Kwast T, Boutros PC, Bristow RG, et al. Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image-guided radiotherapy without hormone therapy. International Journal of Radiation Oncology, Biology, Physics. PMID 30170099 DOI: 10.1016/J.Ijrobp.2018.08.030 |
0.561 |
|
| 2018 |
Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, et al. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30108099 DOI: 10.1158/1055-9965.Epi-18-0369 |
0.571 |
|
| 2018 |
Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, ... ... Davicioni E, et al. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. European Urology. PMID 29853306 DOI: 10.1016/J.Eururo.2018.05.014 |
0.557 |
|
| 2018 |
Torres A, Alshalalfa M, Davicioni E, Gupta A, Yegnasubramanian S, Wheelan SJ, Epstein JI, De Marzo AM, Lotan TL. ETS2 is a prostate basal cell marker and is highly expressed in prostate cancers aberrantly expressing p63. The Prostate. PMID 29761525 DOI: 10.1002/Pros.23646 |
0.487 |
|
| 2018 |
Alshalalfa M, Karnes RJ, Sharma V, Choeurng V, Al-Deen Ashab H, Erho N, Trock BJ, Ross AE, Yousefi K, Tsai HK, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, ... ... Davicioni E, et al. Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29760221 DOI: 10.1158/1078-0432.Ccr-17-2745 |
0.588 |
|
| 2018 |
Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, ... ... Davicioni E, et al. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. PMID 29757368 DOI: 10.1093/Gigascience/Giy050 |
0.54 |
|
| 2018 |
Yang L, Roberts D, Takhar M, Erho N, Bibby BAS, Thiruthaneeswaran N, Bhandari V, Cheng WC, Haider S, McCorry AMB, McArt D, Jain S, Alshalalfa M, Ross A, Schaffer E, ... ... Davicioni E, et al. Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. Ebiomedicine. PMID 29729848 DOI: 10.1016/J.Ebiom.2018.04.019 |
0.531 |
|
| 2018 |
Tosco L, Laenen A, Gevaert T, Salmon I, Decaestecker C, Davicioni E, Buerki C, Claessens F, Swinnen J, Goffin K, Oyen R, Everaerts W, Moris L, De Meerleer G, Haustermans K, et al. Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. Bmc Cancer. 18: 354. PMID 29606109 DOI: 10.1186/S12885-018-4275-Z |
0.527 |
|
| 2018 |
Abou-Ouf H, Alshalalfa M, Takhar M, Erho N, Donnelly B, Davicioni E, Karnes RJ, Bismar TA. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer. Journal of Cancer Research and Clinical Oncology. PMID 29511883 DOI: 10.1007/S00432-018-2615-7 |
0.583 |
|
| 2018 |
Mahal BA, Yang DD, Wang NQ, Alshalalfa M, Davicioni E, Choeurng V, Schaeffer EM, Ross AE, Spratt DE, Den RB, Martin NE, Mouw KW, Orio PF, Choueiri TK, Taplin ME, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. European Urology. PMID 29478736 DOI: 10.1200/Jco.2018.36.6_Suppl.59 |
0.538 |
|
| 2018 |
Muralidhar V, Spratt D, Feng F, Davicioni E, Yousefi K, Zhang J, Wang Q, Choeurng V, Nguyen P. Genomic Validation of Three-Tiered Sub-Classification of High-Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S99. DOI: 10.1200/Jco.2019.37.7_Suppl.17 |
0.558 |
|
| 2018 |
Morgan TM, Miller DC, Dunn R, Susan L, Okoth L, Johnson A, Feng FY, Khurshid G, Davicioni E, Du Plessis M, Montie JE, Cher ML. Prospective randomized trial of genomic classifier impact on treatment decisions in patients at high risk of recurrence following radical prostatectomy (G-MINOR). Journal of Clinical Oncology. 36: TPS154-TPS154. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps154 |
0.437 |
|
| 2018 |
Cooperberg MR, Erho N, Chan JM, Feng FY, Zhao S, Simko J, Cowan JE, Lehrer J, Fishbane N, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Du Plessis M, ... ... Davicioni E, et al. The diverse genomic landscape of low−risk prostate cancer. Journal of Clinical Oncology. 36: 74-74. DOI: 10.1200/Jco.2018.36.6_Suppl.74 |
0.567 |
|
| 2018 |
Gore JL, Dai D, Den RB, Yousefi K, Le T, Du Plessis M, Padre R, Sosu-Sedzorme W, Davicioni E, Nguyen PL, Ross A. Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry. Journal of Clinical Oncology. 36: 72-72. DOI: 10.1200/Jco.2018.36.6_Suppl.72 |
0.485 |
|
| 2018 |
Kim HL, Li P, Huang H, Deheshi S, Knudsen B, Abou-Ouf H, Lam LL, Margrave J, Du Plessis M, Davicioni E, Tosoian JJ, Ross A, Davis JW, Hyndman ME, Klein EA, et al. Validation of a genomic classifier to predict adverse pathology in men diagnosed with low risk prostate cancer. Journal of Clinical Oncology. 36: 71-71. DOI: 10.1200/Jco.2018.36.6_Suppl.71 |
0.513 |
|
| 2018 |
Miyamoto DT, Gibb E, Mouw KW, Liu Y, Wu C, Drumm M, Lehrer J, Ashab HA, Erho N, Du Plessis M, Ong K, Shipley WU, Davicioni E, Efstathiou JA. Genomic profiling of muscle invasive bladder cancer to predict response to bladder-sparing trimodality therapy. Journal of Clinical Oncology. 36: 513-513. DOI: 10.1200/Jco.2018.36.6_Suppl.513 |
0.442 |
|
| 2018 |
Choudhury A, Yang L, Roberts D, Takhar M, Vinayak B, Bibby B, Cheng W, Haider S, Thiruthaneeswaran N, Hoskin P, McArt D, Jain S, Buffa FM, Erho N, Bristow RG, ... ... Davicioni E, et al. Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer. Journal of Clinical Oncology. 36: 5-5. DOI: 10.1200/Jco.2018.36.6_Suppl.5 |
0.575 |
|
| 2018 |
Wright JL, Dall'era M, Bivalacqua T, Seiler R, Liu Y, Gibb E, Wang NQ, Erho N, Alshalalfa M, Davicioni E, Efstathiou JA, Douglas JG, Boormans JL, Van Der Heijden MS, Lotan Y, et al. A genomic classifier for identifying a neuroendocrine-like bladder cancer subtype. Journal of Clinical Oncology. 36: 440-440. DOI: 10.1200/Jco.2018.36.6_Suppl.440 |
0.456 |
|
| 2018 |
Seiler R, Gibb E, Wang NQ, Oo HZ, Lam H, van Kessel KE, Takhar M, Erho N, Winters B, Douglas J, Van Rhijn BW, Sjödahl G, Zwarthoff EC, Thalmann GN, Davicioni E, et al. Apparent plasticity in the biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Journal of Clinical Oncology. 36: 433-433. DOI: 10.1200/Jco.2018.36.6_Suppl.433 |
0.377 |
|
| 2018 |
Nguyen PL, Zhang J, Yousefi K, Davicioni E, Den RB, Feng FY, Spratt DE. Prospective analysis of 4,474 prostate biopsies to evaluate potential treatment management impact of combined clinical-genomic risk classification. Journal of Clinical Oncology. 36: 39-39. DOI: 10.1200/Jco.2018.36.6_Suppl.39 |
0.424 |
|
| 2018 |
Walter R, Jordan J, Takhar M, Alshalalfa M, Dai D, Erho N, Greenberger M, Bradley R, Davicioni E. Genomic variations associated with prostate cancer in large cohort of African American men. Journal of Clinical Oncology. 36: 20-20. DOI: 10.1200/Jco.2018.36.6_Suppl.20 |
0.555 |
|
| 2018 |
Spratt DE, Alshalalfa M, Weiner A, Fishbane N, Mehra R, Walter R, Erho N, Dicker A, Freedland SJ, Karnes J, Glass A, Weinmann S, Davicioni E, Ross A, Den RB, et al. Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass. Journal of Clinical Oncology. 36: 2-2. DOI: 10.1200/Jco.2018.36.6_Suppl.2 |
0.511 |
|
| 2018 |
Kim W, Small EJ, Aggarwal RR, Den RB, Lehrer J, Zhang L, Youngren J, Goldstein TC, Alumkal JJ, Gleave M, Rettig M, Evans CP, Beer TM, Reiter RE, Huang J, ... ... Davicioni E, et al. Luminal and basal subtyping of metastatic castration-resistant prostate cancer (mCRPC) and its clinical implications. Journal of Clinical Oncology. 36: 197-197. DOI: 10.1200/Jco.2018.36.6_Suppl.197 |
0.556 |
|
| 2018 |
Trock BJ, Karnes RJ, Claessens F, Davis JW, Haddad Z, Yousefi K, Davicioni E, Ross A. Validation of a genomic risk classifier to predict metastasis and prostate cancer-specific mortality in men with positive lymph nodes. Journal of Clinical Oncology. 36: 125-125. DOI: 10.1200/Jco.2018.36.6_Suppl.125 |
0.548 |
|
| 2018 |
Gore JL, Du Plessis M, Dai D, Yousefi K, Thompson D, Karsh LI, Lane BR, Franks M, Chen D, Bandyk M, Kibel AS, Kim HL, Lowrance WT, Maroni P, Perrapato SD, ... ... Davicioni E, et al. Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy. Journal of Clinical Oncology. 36: 112-112. DOI: 10.1200/Jco.2018.36.6_Suppl.112 |
0.44 |
|
| 2018 |
Gupta S, Konety BR, Davicioni E, Gibb E. Genomic characterization of variant histology muscle invasive bladder cancer (MIBC) to predict response to therapy. Journal of Clinical Oncology. 36: e24290-e24290. DOI: 10.1200/Jco.2018.36.15_Suppl.E24290 |
0.404 |
|
| 2018 |
Sjostrom M, Chang SL, Fishbane N, Davicioni E, Hartman L, Holmberg E, Feng FY, Speers CW, Pierce LJ, Malmström P, Fernö M, Karlsson P. Comprehensive transcriptomic profiling to identify breast cancer patients that may be spared adjuvant systemic therapy. Journal of Clinical Oncology. 36: 535-535. DOI: 10.1200/Jco.2018.36.15_Suppl.535 |
0.397 |
|
| 2018 |
Rayford W, Jordan J, Takhar M, Alshalalfa M, Dai D, Erho N, Greenberger MD, Davicioni E. Abstract B098: Genomic variations associated with prostate cancer in large cohort of African American men Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B098 |
0.566 |
|
| 2018 |
Den R, Lehrer J, Takhar M, Alshalalfa M, Erho N, Davicioni E, Feng F. Abstract B069: Drug response variability between luminal and basal prostate cancer tumors Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B069 |
0.489 |
|
| 2018 |
Broeck TVd, Moris L, Gevaert T, Smeets E, Prekovic S, Helsen C, Poppel Hv, Everaerts W, Buerki C, Davicioni E, Joniau S, Claessens F. Abstract B065: Genomic analysis of localized prostate cancer identifies AZIN1 as driver of metastatic progression Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B065 |
0.591 |
|
| 2018 |
Berlin A, Chua M, Truong H, Hosni A, Pintilie M, Davicioni E, Dicker A, Van der Kwast T, Bristow R, Den R. OC-0633: Subpathologies and genomic classifier for individualized post-prostatectomy radiotherapy Radiotherapy and Oncology. 127: S337. DOI: 10.1016/S0167-8140(18)30943-5 |
0.37 |
|
| 2018 |
Narayan V, Gibb E, Erho N, Cronican A, Kolisnik T, Davicioni E, Konety B. PD15-01 CHARACTERIZATION OF THE GENOMIC LANDSCAPE OF A PROSPECTIVE MUSCLE-INVASIVE BLADDER CANCER COHORT WITH A FOCUS ON SECONDARY VARIANT HISTOLOGY Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.800 |
0.372 |
|
| 2018 |
Weiner A, Alshalalfa M, Davicioni E, Erho N, Fishbane N, Schaeffer E. MP21-11 IS LOW SOCIOECONOMIC STATUS ASSOCIATED WITH WORSE TUMOR BIOLOGY FOR MEN WITH PROSTATE CANCER? Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.702 |
0.522 |
|
| 2018 |
Trock B, Karnes RJ, Claessens F, Davis J, Haddad Z, Yousefi K, Davicioni E, Ross A. PD60-06 VALIDATION OF A GENOMIC RISK CLASSIFIER TO PREDICT METASTASIS AND PROSTATE CANCER-SPECIFIC MORTALITY IN MEN WITH POSITIVE LYMPH NODES Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2818 |
0.486 |
|
| 2018 |
Lane B, Li P, Huang H, Deheshi S, Marti T, Knudsen B, Abou–Ouf H, Lam L, Aranes M, du Plessis M, Davicioni E, Tosoian J, Ross A, Davis J, Mohler J, et al. PD56-04 VALIDATION OF THE DECIPHER BIOPSY TEST TO PREDICT ADVERSE PATHOLOGY IN MEN DIAGNOSED WITH LOW AND FAVORABLE INTERMEDIATE RISK PROSTATE CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2636 |
0.507 |
|
| 2018 |
Rayford W, Alger J, Takhar M, Jordan J, Yadav K, Alshalalfa M, Dai D, Fishbane N, Scott T, Collins J, Bender B, Ahmed M, Lehrer J, Erho N, Davicioni E, et al. PD56-01 COMPARATIVE GENOMIC ANALYSIS OF 1,043 AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PROSTATE CANCERS: A REPORT FROM THE DECIPHER GRID COLLABORATIVE Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2633 |
0.451 |
|
| 2018 |
Lotan Y, Wright J, Dall'Era MA, Bivalacqua T, Seiler R, Liu Y, Gibb E, Wang Q, Erho N, Alshalalfa M, Davicioni E, Efstathiou JA, Douglas J, Boormans JL, Van der Heijden MS, et al. MP58-19 A GENOMIC CLASSIFIER FOR IDENTIFYING A NEUROENDOCRINE-LIKE BLADDER CANCER SUBTYPE Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1851 |
0.449 |
|
| 2018 |
Seiler R, Gibb EA, Wang NQ, Oo HZ, Lam H, Takhar M, Erho N, van Kessel KE, Winters B, Douglas J, Lopez FV, Crabb SJ, van Rhijn BW, Franzen van de Putte EE, Zwarthoff EC, ... ... Davicioni E, et al. MP54-05 PLASTICITY IN THE BIOLOGICAL RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN MUSCLE-INVASIVE BLADDER CANCER Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1696 |
0.349 |
|
| 2018 |
Echevarria M, Awasthi S, Cheng C, Berglund A, Rounbehler R, Gerke T, Takhar M, Davicioni E, Erho N, Klein E, Freedland S, Ross A, Schaeffer E, Den R, Cleveland J, et al. Novel Genomic Biomarker Panel Predictive of Aggressive Disease in African American Men with Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: e108. DOI: 10.1016/J.Ijrobp.2018.07.399 |
0.46 |
|
| 2018 |
Chua M, Bristow R, Murgic J, Hosni Abdalaty A, Salcedo A, Kamel-Reid S, Fraser M, Zhang J, Wang Q, Ch'ng C, Deheshi S, Davicioni E, Van der Kwast T, Boutros P, Berlin A. A Biopsy Based Genomic Classifier Predicts Biochemical Failure and Metastasis after Definitive Radiation without Hormone Therapy in a Prospective Cohort of Intermediate-Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S99. DOI: 10.1016/J.Ijrobp.2018.06.254 |
0.537 |
|
| 2018 |
Hall W, Liu S, Fishbane N, Xu M, Davicioni E, Mahal B, Den R, Dess R, Jackson W, Wong A, Schaeffer E, Karnes R, Carroll P, Nguyen P, Lawton C, et al. Development and Validation of Genomic Tools to Predict Extraprostatic Extension of Prostate Cancer, Opportunities for Personalizing Treatment International Journal of Radiation Oncology*Biology*Physics. 102: S98. DOI: 10.1016/j.ijrobp.2018.06.252 |
0.439 |
|
| 2018 |
Spratt D, Dess R, Hartman H, Mahal B, Jackson W, Soni P, Alshalalfa M, Fishbane N, Zumsteg Z, Shipley W, Pisansky T, Roach M, Zhao S, Speers C, Davicioni E, et al. Androgen Receptor Activity and Radiotherapeutic Sensitivity in African-American Men with Prostate Cancer: A Large Scale Gene Expression Analysis and Meta-Analysis of RTOG Trials International Journal of Radiation Oncology*Biology*Physics. 102: S3. DOI: 10.1016/J.IJROBP.2018.06.104 |
0.386 |
|
| 2018 |
Pollack A, Giret TM, Chinea FM, Kwon D, Udayakumar TS, Marples B, Abramowitz MC, Stortz J, Lam L, Davicioni E, Buerki C, Stoyanova R. OA20) Association of Circulating Tumor Cells (CTCS) and Genomic Signatures in Prostate Cancer Patients International Journal of Radiation Oncology Biology Physics. 101. DOI: 10.1016/J.Ijrobp.2018.02.059 |
0.541 |
|
| 2018 |
Rai R, Yadav SS, Pan H, Khan I, O'Connor J, Alshalalfa M, Davicioni E, Taioli E, Elemento O, Tewari AK, Yadav KK. Epigenetic analysis identifies factors driving racial disparity in prostate cancer Cancer Reports. 2: e1153. DOI: 10.1002/CNR2.1153 |
0.41 |
|
| 2017 |
Spratt DE, Dai DLY, Den RB, Troncoso P, Yousefi K, Ross AE, Schaeffer EM, Haddad Z, Davicioni E, Mehra R, Morgan TM, Rayford W, Abdollah F, Trabulsi E, Achim M, et al. Performance of a Prostate Cancer Genomic Classifier in Predicting Metastasis in Men with Prostate-specific Antigen Persistence Postprostatectomy. European Urology. PMID 29233664 DOI: 10.1016/J.Eururo.2017.11.024 |
0.561 |
|
| 2017 |
Spratt DE, Zhang J, Santiago-Jiménez M, Dess RT, Davis JW, Den RB, Dicker AP, Kane CJ, Pollack A, Stoyanova R, Abdollah F, Ross AE, Cole A, Uchio E, Randall JM, ... ... Davicioni E, et al. Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017742940. PMID 29185869 DOI: 10.1200/Jco.2017.74.2940 |
0.49 |
|
| 2017 |
Tsai HK, Lehrer J, Alshalalfa M, Erho N, Davicioni E, Lotan TL. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma. Bmc Cancer. 17: 759. PMID 29132337 DOI: 10.1186/S12885-017-3729-Z |
0.56 |
|
| 2017 |
Sharma V, Yousefi K, Haddad Z, Buerki C, Jenkins RB, Davicioni E, Karnes RJ. Gene Expression Correlates of Site-Specific Metastasis among Men with Lymph Node Positive Prostate Cancer Treated with Radical Prostatectomy: a Case Series. Urology. PMID 29079212 DOI: 10.1016/J.Urology.2017.10.016 |
0.459 |
|
| 2017 |
Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J, Ekram MB, Li B, Davicioni E, Takhar M, Erho N, et al. LSD1-Mediated Epigenetic Reprogramming Drives CENPE Expression and Prostate Cancer Progression. Cancer Research. PMID 28916652 DOI: 10.1158/0008-5472.Can-17-0496 |
0.497 |
|
| 2017 |
Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28899973 DOI: 10.1158/1078-0432.Ccr-17-0413 |
0.566 |
|
| 2017 |
Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LLC, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, ... ... Davicioni E, et al. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. Oncotarget. 8: 50804-50813. PMID 28881605 DOI: 10.18632/Oncotarget.15133 |
0.559 |
|
| 2017 |
Radtke JP, Takhar M, Bonekamp D, Kesch C, Erho N, du Plessis M, Buerki C, Ong K, Davicioni E, Hohenfellner M, Hadaschik BA. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit. European Urology Focus. PMID 28753844 DOI: 10.1016/J.Euf.2017.01.005 |
0.383 |
|
| 2017 |
Urbanucci A, Barfeld SJ, Kytölä V, Itkonen HM, Coleman IM, Vodák D, Sjöblom L, Sheng X, Tolonen T, Minner S, Burdelski C, Kivinummi KK, Kohvakka A, Kregel S, Takhar M, ... ... Davicioni E, et al. Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports. 19: 2045-2059. PMID 28591577 DOI: 10.1016/J.Celrep.2017.05.049 |
0.507 |
|
| 2017 |
Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, ... ... Davicioni E, et al. Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. European Urology. PMID 28528811 DOI: 10.1016/J.Eururo.2017.05.009 |
0.527 |
|
| 2017 |
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, ... ... Davicioni E, et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. Jama Oncology. PMID 28494073 DOI: 10.1001/Jamaoncol.2017.0751 |
0.536 |
|
| 2017 |
Gore JL, Plessis MD, Santiago-Jiménez M, Yousefi K, Thompson DJS, Karsh L, Lane BR, Franks M, Chen DYT, Bandyk M, Bianco FJ, Brown G, Clark W, Kibel AS, Kim HL, ... ... Davicioni E, et al. Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study. Cancer. PMID 28422278 DOI: 10.1002/Cncr.30665 |
0.46 |
|
| 2017 |
Itkonen HM, Brown M, Urbanucci A, Tredwell G, Ho Lau C, Barfeld S, Hart C, Guldvik IJ, Takhar M, Heemers HV, Erho N, Bloch K, Davicioni E, Derua R, Waelkens E, et al. Lipid degradation promotes prostate cancer cell survival. Oncotarget. PMID 28415728 DOI: 10.18632/Oncotarget.16123 |
0.521 |
|
| 2017 |
Seiler R, Oo HZ, Tortora D, Clausen TM, Wang CK, Kumar G, Pereira MA, Ørum-Madsen MS, Agerbæk MØ, Gustavsson T, Nordmaj MA, Rich JR, Lallous N, Fazli L, Lee SS, ... ... Davicioni E, et al. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. European Urology. PMID 28408175 DOI: 10.1016/J.Eururo.2017.03.021 |
0.401 |
|
| 2017 |
Karnes RJ, Choeurng V, Ross AE, Schaeffer EM, Klein EA, Freedland SJ, Erho N, Yousefi K, Takhar M, Davicioni E, Cooperberg MR, Trock BJ. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. European Urology. PMID 28400167 DOI: 10.1016/J.Eururo.2017.03.036 |
0.546 |
|
| 2017 |
Seiler R, Ashab HA, Erho N, van Rhijn BW, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, ... Davicioni E, et al. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. European Urology. PMID 28390739 DOI: 10.1016/J.Eururo.2017.03.030 |
0.379 |
|
| 2017 |
Spratt DE, Yousefi K, Deheshi S, Ross AE, Den RB, Schaeffer EM, Trock BJ, Zhang J, Glass AG, Dicker AP, Abdollah F, Zhao SG, Lam LL, du Plessis M, Choeurng V, ... ... Davicioni E, et al. Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016702811. PMID 28358655 DOI: 10.1200/Jco.2016.70.2811 |
0.464 |
|
| 2017 |
Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, Briganti A, Davicioni E, Abdollah F. Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016699918. PMID 28350520 DOI: 10.1016/J.Juro.2017.02.3182 |
0.493 |
|
| 2017 |
Torres A, Alshalalfa M, Tomlins SA, Erho N, Gibb EA, Chelliserry J, Lim L, Lam LL, Faraj SF, Bezerra SM, Davicioni E, Yousefi K, Ross AE, Netto GJ, Schaeffer EM, et al. Comprehensive Determination of Prostate Tumor ETS Gene Status in Clinical Samples Using the CLIA Decipher Assay. The Journal of Molecular Diagnostics : Jmd. PMID 28341589 DOI: 10.1016/J.Jmoldx.2017.01.007 |
0.505 |
|
| 2017 |
Mo F, Lin D, Takhar M, Ramnarine VR, Dong X, Bell RH, Volik SV, Wang K, Xue H, Wang Y, Haegert A, Anderson S, Brahmbhatt S, Erho N, Wang X, ... ... Davicioni E, et al. Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. European Urology. PMID 28330676 DOI: 10.1016/J.Eururo.2017.02.038 |
0.567 |
|
| 2017 |
Wahl DR, Nguyen PL, Santiago M, Yousefi K, Davicioni E, Shumway DA, Speers C, Mehra R, Feng FY, Osborne JR, Spratt DE. Pan-Cancer Analysis of Genomic Sequencing Among the Elderly. International Journal of Radiation Oncology, Biology, Physics. PMID 28258894 DOI: 10.1016/J.Ijrobp.2017.01.002 |
0.316 |
|
| 2017 |
Kiss B, Wyatt AW, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Buerki C, Davicioni E, Collins C, Thalmann GN, et al. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Scientific Reports. 7: 42713. PMID 28205537 DOI: 10.1038/Srep42713 |
0.398 |
|
| 2017 |
Alshalalfa M, Verhaegh GW, Gibb EA, Santiago-Jiménez M, Erho N, Jordan J, Yousefi K, Lam LL, Kolisnik T, Chelissery J, Seiler R, Ross AE, Karnes RJ, Schaeffer EM, Lotan TT, ... ... Davicioni E, et al. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: Exploratory analysis from 12,076 patients. Oncotarget. PMID 28187449 DOI: 10.18632/oncotarget.15133 |
0.473 |
|
| 2017 |
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, ... ... Davicioni E, et al. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget. PMID 28145883 DOI: 10.18632/Oncotarget.14850 |
0.458 |
|
| 2017 |
Kim H, Kalchman I, Santiago-Jiménez M, Lehrer J, Guo J, Hermann G, Yamoah K, Alshalalfa M, Huang HC, Ross AE, Schaeffer EM, Davicioni E, Erho N, Yousefi K, Den RB. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes. Cancer. PMID 28140459 DOI: 10.1002/Cncr.30580 |
0.442 |
|
| 2017 |
Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY. Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 28117383 DOI: 10.1038/pcan.2016.58 |
0.435 |
|
| 2017 |
Pellegrini KL, Sanda MG, Patil D, Long Q, Santiago-Jiménez M, Takhar M, Erho N, Yousefi K, Davicioni E, Klein EA, Jenkins RB, Karnes RJ, Moreno CS. Evaluation of a 24-Gene Signature for Prognosis of Metastatic Events and Prostate Cancer-Specific Mortality. Bju International. PMID 28107602 DOI: 10.1111/Bju.13779 |
0.573 |
|
| 2017 |
Tse BW, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, ... ... Davicioni E, et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. PMID 28092670 DOI: 10.1038/Onc.2016.482 |
0.47 |
|
| 2017 |
Nguyen PL, Haddad Z, Lam LL, Ong K, Buerki C, Deheshi S, Yousefi K, Davicioni E, Tosoian JJ, Lotan TL, Feng FY, Trock BJ, Ross A, Klein EA. Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens. Journal of Clinical Oncology. 35: 4-4. DOI: 10.1200/Jco.2017.35.6_Suppl.4 |
0.562 |
|
| 2017 |
Alshalalfa M, Santiago-Jimenez M, Erho N, Fishbane N, Yousefi K, Ashab HA, Davicioni E, Ross A, Schaeffer EM. Relationships between an androgen receptor output signature (ARoS), AR expression, and poor prostate cancer prognosis in RP tissues. Journal of Clinical Oncology. 35: 38-38. DOI: 10.1200/Jco.2017.35.6_Suppl.38 |
0.522 |
|
| 2017 |
Feng FY, Zhao S, Chang SL, Erho N, Lehrer J, Alshalalfa M, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas EM, Klein EA, Davicioni E, Ross A, et al. Luminal and basal subtyping of prostate cancer. Journal of Clinical Oncology. 35: 3-3. DOI: 10.1200/Jco.2017.35.6_Suppl.3 |
0.568 |
|
| 2017 |
Efstathiou JA, Gibb E, Miyamoto DT, Wu C, Drumm M, Lehrer J, Ashab HA, Erho N, du Plessis M, Ong K, Bhat A, Mouw KW, Davicioni E, Shipley WU. Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy. Journal of Clinical Oncology. 35: 287-287. DOI: 10.1200/Jco.2017.35.6_Suppl.287 |
0.443 |
|
| 2017 |
Seiler R, Winters B, Douglas J, van Rhijn BW, Sjödahl G, Lerner SP, Hoadley KA, North SA, McConkey DJ, Choi W, Kim WY, van Kessel KE, Thalmann GN, Davicioni E, Crabb SJ, et al. Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. Journal of Clinical Oncology. 35: 281-281. DOI: 10.1200/Jco.2017.35.6_Suppl.281 |
0.402 |
|
| 2017 |
Gore JL, du Plessis M, Santiago-Jimenez M, Yousefi K, Thompson D, Chen D, Clark W, Franks M, Karsh LI, Kibel AS, Kim HL, Lane BR, Lotan Y, Lowrance WT, Maroni P, ... ... Davicioni E, et al. Effect of decipher test on adjuvant treatment decision-making among men with high-risk pathology at radical prostatectomy: Results from a multicenter prospective PRO-IMPACT study. Journal of Clinical Oncology. 35: 24-24. DOI: 10.1200/Jco.2017.35.6_Suppl.24 |
0.37 |
|
| 2017 |
Sweeney C, Gerke T, Beltran H, Sboner A, Karnes RJ, Klein EA, Davicioni E, Yousefi K, Ross A, Mucci L, Trock BJ. Association of loss of tumor suppressor ZFP36 with lethal prostate cancer. Journal of Clinical Oncology. 35: 5062-5062. DOI: 10.1200/Jco.2017.35.15_Suppl.5062 |
0.561 |
|
| 2017 |
Spratt D, Dess R, Zhang J, Santiago-Jiménez M, Davis J, Den R, Dicker A, Kane C, Pollack A, Ross A, du Plessis M, Choeurng V, Haddad Z, Davicioni E, Weinmann S, et al. Development and Validation of a Novel Clinical-Genomic Risk Group Classification for Prostate Cancer Incorporating Genomic and Clinicopathologic Risk International Journal of Radiation Oncology*Biology*Physics. 99: S97. DOI: 10.1200/Jco.2017.35.15_Suppl.5000 |
0.558 |
|
| 2017 |
Spratt DE, Zhang J, Santiago-Jimenez M, Davis JW, Den RB, Dicker A, Kane CJ, Pollack A, Ross A, du Plessis M, Choeurng V, Yousefi K, Haddad Z, Davicioni E, Weinmann S, et al. Development and validation of a novel clinical-genomic risk group classification for prostate cancer incorporating genomic and clinicopathologic risk. Journal of Clinical Oncology. 35: 5000-5000. DOI: 10.1200/jco.2017.35.15_suppl.5000 |
0.392 |
|
| 2017 |
Volpert M, Tse B, Ratther E, Stylianou N, Nouri M, Lehman M, McPherson S, Roshan-Moniri M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins R, Ross A, Karnes J, et al. Abstract 4908: Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastatic progression and patient mortality Cancer Research. 77: 4908-4908. DOI: 10.1158/1538-7445.Am2017-4908 |
0.543 |
|
| 2017 |
Hadaschik B, Takha M, Radtke J, Bonekamp D, Du Plessis M, Buerki C, Erho N, Ong K, Davicioni E. Transcriptome wide analysis of MRI-targeted biopsy and matching surgical specimens from high-risk prostate cancer patients treated with radical prostatectomy European Urology Supplements. 16: e871-e872. DOI: 10.1016/S1569-9056(17)30562-6 |
0.456 |
|
| 2017 |
Broeck TVD, Gevaert T, Prekovic S, Ong K, Tosco L, Moris L, Smeets E, Lehrer J, Haddad Z, Helsen C, Margrave J, Poppel HV, Everaerts W, Erho N, Buerki C, ... Davicioni E, et al. A genomic analysis of metastases-prone localized prostate cancer in a European high-risk population European Urology Supplements. 16. DOI: 10.1016/S1569-9056(17)30543-2 |
0.54 |
|
| 2017 |
Cooperberg M, Erho N, Chan J, Feng F, Cowan J, Simko J, Ong K, Alshalalfa M, Kolisnik T, Margrave J, Aranes M, Du Plessis M, Buerki C, Zhao S, Tenggara I, ... Davicioni E, et al. The diverse genomic landscape of low-risk prostate cancer European Urology Supplements. 16: e427-e428. DOI: 10.1016/S1569-9056(17)30311-1 |
0.469 |
|
| 2017 |
Seiler R, Gibb EA, Takhar M, Kessel KV, van Rhijn BW, Winters B, Douglas J, Wang Q, Choeurng V, Erho N, Buerki C, Davicioni E, Sjödahl G, Thalmann GN, Zwarthoff EC, et al. Plasticity in muscle-invasive bladder cancer before and after cisplatin-based neoadjuvant chemotherapy Urologic Oncology: Seminars and Original Investigations. 35: 618. DOI: 10.1016/J.Urolonc.2017.06.034 |
0.345 |
|
| 2017 |
Cooperberg MR, Erho N, Chan JM, Feng FY, Cowan JE, Ong K, Alshalalfa M, Kolisnik T, Margrave J, Aranes M, du Plessis M, Buerki C, Zhao SG, Tenggara I, Davicioni E, et al. PNFBA-09 THE DIVERSE GENOMIC LANDSCAPE OF LOW-RISK PROSTATE CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3238 |
0.555 |
|
| 2017 |
Achim M, Matin S, Chapin B, Troncoso P, Li Ning Tapia E, Guerrero M, Prokhorova I, Olson A, Haddad Z, Margrave J, Chelliserry J, Lam L, Yousefi K, Buerki C, Davicioni E, et al. MP64-12 ASSESSING DECIPHER FOR PREDICTING LYMPH NODE POSITIVE DISEASE AMONG MEN DIAGNOSED WITH INTERMEDIATE RISK DISEASE TREATED WITH PROSTATECTOMY AND EPLND Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1985 |
0.344 |
|
| 2017 |
Abdollah F, Ashab HA, Karnes RJ, Davis JW, Erho N, Wang Q, Gibb EA, Haddad Z, Choeurng V, Yousefi K, Davicioni E, Kane CJ, Den R, Ross AE, Klein EA. Mp57-18 Development And Validation Of Novel Genomic Classifiers For Prediction Of Adverse Pathology After Prostatectomy The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1792 |
0.385 |
|
| 2017 |
Kiss B, Wyatt A, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, Buerki C, Davicioni E, Collins C, Thalmann G, et al. MP44-08 THE LANDSCAPE OF HER2 ALTERATIONS IN MUSCLE-INVASIVE BLADDER CANCER: IMPACT ON PATIENT SELECTION FOR TARGETED THERAPIES? Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1339 |
0.352 |
|
| 2017 |
Seiler R, Ashab HAD, Erho N, Rhijn BWGv, Winters B, Douglas J, Kessel KV, Putte EEFvd, Sommerlad M, Wang Q, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, ... Davicioni E, et al. Mp34-01 Molecular Subtypes Of Muscle Invasive Bladder Cancer Are Related To Benefit From Neoadjuvant Chemotherapy: Development Of A Single Sample Patient Assay The Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.1018 |
0.36 |
|
| 2016 |
Stoyanova R, Takhar M, Tschudi Y, Ford JC, Solórzano G, Erho N, Balagurunathan Y, Punnen S, Davicioni E, Gillies RJ, Pollack A. Prostate cancer radiomics and the promise of radiogenomics. Translational Cancer Research. 5: 432-447. PMID 29188191 DOI: 10.21037/Tcr.2016.06.20 |
0.589 |
|
| 2016 |
Lobo JM, Trifiletti DM, Sturz VN, Dicker AP, Buerki C, Davicioni E, Cooperberg MR, Karnes RJ, Jenkins RB, Den RB, Showalter TN. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer. Clinical Genitourinary Cancer. PMID 28089723 DOI: 10.1016/J.Clgc.2016.08.012 |
0.53 |
|
| 2016 |
Das R, Gregory PA, Fernandes RC, Denis I, Wang Q, Townley SL, Zhao SG, Hanson A, Pickering MA, Armstrong HK, Lokman NA, Ebrahimie E, Davicioni E, Jenkins RB, Karnes RJ, et al. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2. Cancer Research. PMID 28011622 DOI: 10.1158/0008-5472.Can-16-2529 |
0.386 |
|
| 2016 |
Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, Alshalalfa M, Glavaris S, Simons BW, Tran P, Davicioni E, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer and Prostatic Diseases. PMID 27801901 DOI: 10.1038/pcan.2016.49 |
0.341 |
|
| 2016 |
Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, et al. Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. The Lancet. Oncology. PMID 27743920 DOI: 10.1016/S1470-2045(16)30491-0 |
0.548 |
|
| 2016 |
Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HA, Takhar M, Olson A, Lam LL, Kelly WK, Knudsen KE, et al. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report. Urology Case Reports. 9: 51-54. PMID 27713863 DOI: 10.1016/J.Eucr.2016.08.010 |
0.475 |
|
| 2016 |
Nguyen PL, Martin NE, Palmer-Aronsten BJ, Choeurng V, Kolisnik T, Beard CJ, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng F. The Use of a Biopsy-Based Genomic Classifier to Predict the Risk of Distant Metastasis After Definitive Radiation and Short-Course Androgen Deprivation Therapy for Intermediate- and High-Risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: S113-S114. PMID 27675556 DOI: 10.1016/j.ijrobp.2016.06.279 |
0.451 |
|
| 2016 |
Den RB, Davicioni E, Takhar M, Erho NG, Lam L, Ashab HA, Olson A, Dillon M, Yousefi K, Wood P, Alshalafa M. The Frequency of Druggable Targets in Localized Prostate Cancer: Initial Analysis From a Commercially Available Genomic Expression Database in Urologic Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: E251-E252. PMID 27674178 DOI: 10.1016/j.ijrobp.2016.06.1254 |
0.437 |
|
| 2016 |
Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, et al. Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential. The Journal of Urology. PMID 27569435 DOI: 10.1016/J.Juro.2016.08.091 |
0.539 |
|
| 2016 |
White NM, Zhao SG, Zhang J, Rozycki EB, Dang HX, McFadden SD, Eteleeb AM, Alshalalfa M, Vergara IA, Erho N, Arbeit JM, Karnes RJ, Den RB, Davicioni E, Maher CA. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer. European Urology. PMID 27460352 DOI: 10.1016/J.Eururo.2016.07.012 |
0.548 |
|
| 2016 |
Stoyanova R, Pollack A, Takhar M, Lynne C, Parra N, Lam LL, Alshalalfa M, Buerki C, Castillo R, Jorda M, Ashab HA, Kryvenko ON, Punnen S, Parekh DJ, Abramowitz MC, ... ... Davicioni E, et al. Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget. PMID 27438142 DOI: 10.18632/Oncotarget.10523 |
0.557 |
|
| 2016 |
Lee HJ, Yousefi K, Haddad Z, Abdollah F, Lam LL, Shin H, Alshalalfa M, Godebu E, Wang S, Shabaik A, Davicioni E, Kane CJ. Evaluation of a genomic classifier in radical prostatectomy patients with lymph node metastasis. Research and Reports in Urology. 8: 77-84. PMID 27419104 DOI: 10.2147/Rru.S99997 |
0.318 |
|
| 2016 |
You S, Knudsen BS, Erho N, Alshalalfa M, Takhar M, Al-Deen Ashab H, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR. Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome. Cancer Research. PMID 27302169 DOI: 10.1158/0008-5472.Can-16-0902 |
0.497 |
|
| 2016 |
Johnson MH, Ross AE, Alshalalfa M, Erho N, Yousefi K, Glavaris S, Fedor H, Han M, Faraj SF, Bezerra SM, Netto G, Partin AW, Trock BJ, Davicioni E, Schaeffer EM. SPINK1 defines a molecular subtype of prostate cancer in men with more rapid progression in an at-risk, natural history radical prostatectomy cohort. The Journal of Urology. PMID 27238617 DOI: 10.1016/J.Juro.2016.05.092 |
0.562 |
|
| 2016 |
Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, et al. Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk. Prostate Cancer and Prostatic Diseases. PMID 27136742 DOI: 10.1016/J.Ijrobp.2016.06.256 |
0.343 |
|
| 2016 |
Seiler R, Lam LL, Erho N, Takhar M, Mitra AP, Buerki C, Davicioni E, Skinner EC, Daneshmand S, Black PC. Prediction of lymph node metastasis in bladder cancer patients using whole transcriptome gene expression signatures. The Journal of Urology. PMID 27105761 DOI: 10.1016/J.Juro.2016.04.061 |
0.405 |
|
| 2016 |
Spans L, Van den Broeck T, Smeets E, Prekovic S, Thienpont B, Lambrechts D, Karnes RJ, Erho N, Alshalalfa M, Davicioni E, Helsen C, Gevaert T, Tosco L, Haustermans K, et al. Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1. Oncotarget. PMID 27014907 DOI: 10.18632/Oncotarget.8220 |
0.523 |
|
| 2016 |
Knudsen BS, Kim HL, Erho N, Shin H, Alshalalfa M, Lam LL, Tenggara I, Chadwich K, Van Der Kwast T, Fleshner N, Davicioni E, Carroll PR, Cooperberg MR, Chan JM, Simko JP. Application of a Clinical Whole-Transcriptome Assay for Staging and Prognosis of Prostate Cancer Diagnosed in Needle Core Biopsy Specimens. The Journal of Molecular Diagnostics : Jmd. PMID 26945428 DOI: 10.1016/J.Jmoldx.2015.12.006 |
0.495 |
|
| 2016 |
Klein EA, Haddad Z, Yousefi K, Lam LL, Wang Q, Choeurng V, Palmer-Aronsten B, Buerki C, Davicioni E, Li J, Kattan MW, Stephenson AJ, Magi-Galluzzi C. Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk. Urology. PMID 26809071 DOI: 10.1016/J.Urology.2016.01.012 |
0.532 |
|
| 2016 |
Freedland SJ, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam LL, Buerki C, Ra S, Robbins B, Trabulsi EJ, Shah NL, Abdollah F, Feng FY, Davicioni E, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. European Urology. PMID 26806658 DOI: 10.1016/J.Eururo.2016.01.008 |
0.476 |
|
| 2016 |
Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, et al. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. The Prostate. PMID 26771938 DOI: 10.1002/Pros.23151 |
0.545 |
|
| 2016 |
Evans JR, Zhao SG, Chang SL, Tomlins SA, Erho N, Sboner A, Schiewer MJ, Spratt DE, Kothari V, Klein EA, Den RB, Dicker AP, Karnes RJ, Yu X, Nguyen PL, ... ... Davicioni E, et al. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer. Jama Oncology. 1-10. PMID 26746117 DOI: 10.1001/Jamaoncol.2015.4955 |
0.524 |
|
| 2016 |
Faraj SF, Bezerra SM, Yousefi K, Fedor H, Glavaris S, Han M, Partin AW, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock BJ, Schaeffer EM, Ross AE, Netto GJ. Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. Plos One. 11: e0146189. PMID 26731672 DOI: 10.1371/Journal.Pone.0146189 |
0.463 |
|
| 2016 |
Stoyanova R, Takhar M, Tschudi Y, Ford JC, Solórzano G, Erho N, Balagurunathan Y, Punnen S, Davicioni E, Gillies RJ, Pollack A. Prostate cancer radiomics and the promise of radiogenomics Translational Cancer Research. 5: 432-447. DOI: 10.21037/tcr.2016.06.20 |
0.439 |
|
| 2016 |
Erho N, Alshalalfa M, Wood PJ, Takhar M, Ashab HA, Davicioni E. The frequency of druggable targets in localized prostate cancer: Initial analysis from the Decipher GRID. Journal of Clinical Oncology. 34: 98-98. DOI: 10.1200/Jco.2016.34.2_Suppl.98 |
0.551 |
|
| 2016 |
Magi-Galluzzi C, Yousefi K, Haddad Z, Palmer-Aronsten B, Lam LL, Buerki C, Li J, Kattan MW, Stephenson AJ, Davicioni E, Klein EA. Validation of the Decipher prostate cancer classifier for predicting 10-year postoperative metastasis from analysis of diagnostic needle biopsy specimens. Journal of Clinical Oncology. 34: 59-59. DOI: 10.1200/Jco.2016.34.2_Suppl.59 |
0.545 |
|
| 2016 |
Den RB, Choeurng V, Howard L, de Hoedt A, Du Plessis M, Yousefi K, Lam LL, Buerki C, Trabulsi EJ, Dicker A, Davicioni E, Karnes J, Freedland SJ. Validation of a genomic classifier for prediction of metastasis following postoperative salvage radiation therapy. Journal of Clinical Oncology. 34: 4-4. DOI: 10.1200/jco.2016.34.2_suppl.4 |
0.421 |
|
| 2016 |
Alshalalfa M, Tsai H, Haddad Z, Ross A, Karnes RJ, Davicioni E, Schaeffer EM, Lotan TL. Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility. Journal of Clinical Oncology. 34: 303-303. DOI: 10.1200/Jco.2016.34.2_Suppl.303 |
0.53 |
|
| 2016 |
Ross A, Zhao G, Benzon B, Takhar M, Haffner M, Erho N, Ghabili K, Tosoian J, Hurley P, Alshalalfa M, Glavaris S, Simons B, Tran P, Davicioni E, Karnes J, et al. 1066 The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy European Urology Supplements. 15: e1066. DOI: 10.1200/Jco.2016.34.2_Suppl.256 |
0.455 |
|
| 2016 |
Ross A, Benzon B, Zhao S, Takhar M, Haffner M, Erho N, Hurley P, Tosoian JJ, Alshalalfa M, Glavaris S, Simons B, Tran PT, Davicioni E, Karnes J, Schaeffer EM, et al. The relationship of B7H3 expression to androgen and prostate cancer outcomes in a large natural history cohort of men undergoing prostatectomy. Journal of Clinical Oncology. 34: 256-256. DOI: 10.1200/jco.2016.34.2_suppl.256 |
0.328 |
|
| 2016 |
Karnes J, Ashab HA, Trock BJ, Ross A, Tsai H, Tosoian JJ, Erho N, Choeurng V, Yousefi K, Haddad Z, Abdollah F, Klein EA, Nguyen PL, Feng FY, Dicker A, ... ... Davicioni E, et al. Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure. Journal of Clinical Oncology. 34: 106-106. DOI: 10.1200/Jco.2016.34.2_Suppl.106 |
0.526 |
|
| 2016 |
Gore JL, Du Plessis M, Santiago-Jimenez M, Yousefi K, Thompson DJS, Chen DYT, Clark WR, Franks ME, Karsh LI, Kibel AS, Lane BR, Lotan Y, Lowrance WT, Maroni P, Perrapato SD, ... ... Davicioni E, et al. Effect of a genomic classifier on treatment decision-making among patients with biochemical recurrence after radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study. Journal of Clinical Oncology. 34: e16558-e16558. DOI: 10.1200/Jco.2016.34.15_Suppl.E16558 |
0.351 |
|
| 2016 |
Karnes J, Ross A, Schaeffer EM, Klein EA, Erho N, Yousefi K, Takhar M, Davicioni E, Trock BJ. Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients. Journal of Clinical Oncology. 34: 5056-5056. DOI: 10.1200/Jco.2016.34.15_Suppl.5056 |
0.498 |
|
| 2016 |
Alshalalfa M, Tsai H, Haddad Z, Ross A, Karnes J, Davicioni E, Schaeffer EM, Lotan TL. Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility in radical prostatectomy tissues. Journal of Clinical Oncology. 34: 5055-5055. DOI: 10.1200/Jco.2016.34.15_Suppl.5055 |
0.538 |
|
| 2016 |
Gore JL, Du Plessis M, Santiago-Jimenez M, Yousefi K, Thompson DJS, Chen DYT, Clark WR, Franks ME, Karsh LI, Kibel AS, Kim HL, Lane BR, Lotan Y, Lowrance WT, Maroni P, ... ... Davicioni E, et al. Effect of a genomic classifier on adjuvant treatment decision-making among patients with high-risk pathology at radical prostatectomy: Results from the multicenter prospective PRO-IMPACT study. Journal of Clinical Oncology. 34: 5053-5053. DOI: 10.1200/Jco.2016.34.15_Suppl.5053 |
0.399 |
|
| 2016 |
Karnes J, Ashab HA, Trock BJ, Ross A, Tsai H, Tosoian JJ, Alshalalfa M, Choeurng V, Yousefi K, Haddad Z, Abdollah F, Klein EA, Nguyen PL, Feng FY, Dicker A, ... ... Davicioni E, et al. Development and validation of genomic signature to predict ADT treatment failure. Journal of Clinical Oncology. 34: 5018-5018. DOI: 10.1200/Jco.2016.34.15_Suppl.5018 |
0.553 |
|
| 2016 |
You S, Knudsen B, Erho N, Alshalalfa M, Takhar M, Ashab HA, Davicioni E, Karnes RJ, Klein EA, Den RB, Ross AE, Schaeffer EM, Garraway IP, Kim J, Freeman MR. Abstract 1502: Three intrinsic subtypes of prostate cancer with distinct pathway activation profiles differ in prognosis and treatment response Cancer Research. 76: 1502-1502. DOI: 10.1158/1538-7445.Am2016-1502 |
0.537 |
|
| 2016 |
Klein E, Haddad Z, Yousefi K, Lam L, Wang Q, Choeurng V, Palmer-Aronsten B, Buerki C, Davicioni E, Li J, Kattan M, Stephenson A, Magi-Galluzzi C. 730 Decipher genomic classifier measured on prostate biopsy predicts 10 year metastasis risk European Urology Supplements. 15: e730. DOI: 10.1016/S1569-9056(16)60732-7 |
0.426 |
|
| 2016 |
Den R, Yousefi K, Trock BJ, Davicioni E, Tosoian JJ, Thompson DJS, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Dicker A, et al. Efficacy of early and delayed radiation in a prostatectomy cohort adjusted for genomic and clinical risk. Journal of Clinical Oncology. 34: 12-12. DOI: 10.1016/S1569-9056(16)60437-2 |
0.493 |
|
| 2016 |
Seiler R, Choi W, Erho N, Kiss B, Lam LL, Wang Q, Bürki C, Davicioni E, Thalmann GN, McConkey DJ, Black PC. PD33-11 NEOADJUVANT CHEMOTHERAPY IN BLADDER CANCER: P53-NESS IS ASSOCIATED WITH CHEMO-RESISTANCE AND UNFAVORABLE OUTCOME Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.720 |
0.316 |
|
| 2016 |
Ross A, Den R, Yousefi K, Trock B, Davicioni E, Tosoian J, Thompson D, Choeurng V, Haddad Z, Tran P, Trabulsi E, Gomella L, Lallas C, Abdollah F, Feng F, et al. MP14-12 EFFICACY OF EARLY AND DELAYED RADIATION IN A PROSTATECTOMY COHORT ADJUSTED FOR GENOMIC AND CLINICAL RISK Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2515 |
0.367 |
|
| 2016 |
Karnes RJ, Ashab HA, J. Trock B, E. Ross A, Tsai H, J. Tosoian J, Erho N, Alshalafa M, Choeurng V, Yousefi K, Takhar M, Haddad Z, Abdollah F, A. Klein E, L. Nguyen P, ... ... Davicioni E, et al. MP07-20 DEVELOPMENT AND VALIDATION OF GENOMIC SIGNATURE THAT PREDICTS ADT TREATMENT FAILURE Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2223 |
0.521 |
|
| 2016 |
Davicioni E, Erho N, Lam L, Takhar M, Ashab HA, Olson A, Dillon M, yousefi k, haddad z, Wood P, alshalalfa m. Mp07-10 The Frequency Of Druggable Targets In Localized Prostate Cancer: Initial Analysis From The Decipher Grid The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2213 |
0.478 |
|
| 2016 |
Abdollah F, Alter J, Haddad Z, Santiago M, Yousefi K, Lam L, Choeurng V, Schleikelman M, Buerki C, Davicioni E, Patel V, Shah NL. MP07-07 PREDICTING ADVERSE PATHOLOGICAL OUTCOMES IN PROSTATE CANCER (PCA) PATIENTS UNDERGOING RADICAL PROSTATECTOMY (RP): THE ROLE OF GENOMIC SIGNATURE. Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2210 |
0.562 |
|
| 2016 |
Karnes RJ, Ross A, Schaeffer E, Klein E, Erho N, Yousefi K, Takhar M, Davicioni E, Trock B. MP07-01 VALIDATION OF A GENOMIC RISK CLASSIFIER TO PREDICT PROSTATE CANCER DEATH IN HIGH RISK PATIENTS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.2204 |
0.533 |
|
| 2016 |
Lee HJ, Yousefi K, Haddad Z, Abdollah F, Lam L, Shin H, Alshalalfa M, Godebu E, Wang S, Shabaik A, Davicioni E, Kane C. MP02-06 EVALUATION OF A GENOMIC CLASSIFIER IN RADICAL PROSTATECTOMY PATIENTS WITH LYMPH NODE METASTASIS Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1878 |
0.48 |
|
| 2016 |
Kim H, Alshalalfa M, Hoffman-Censits J, Lallas CD, Davicioni E, Lin J, Birbe R, Erho N, Lehrer J, Ashab HAD, Takhar M, Olson A, Lam LLC, Kelly WK, Knudsen KE, et al. Potential Impact on Clinical Decision Making via a Genome-Wide Expression Profiling: A Case Report Urology Case Reports. 9: 51-54. DOI: 10.1016/j.eucr.2016.08.010 |
0.373 |
|
| 2015 |
Zhao SG, Evans JR, Kothari V, Sun G, Larm A, Mondine V, Schaeffer EM, Ross AE, Klein EA, Den RB, Dicker AP, Karnes RJ, Erho N, Nguyen PL, Davicioni E, et al. The landscape of prognostic outlier genes in high-risk prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26631616 DOI: 10.1158/1078-0432.Ccr-15-1250 |
0.559 |
|
| 2015 |
Glass AG, Leo MC, Haddad Z, Yousefi K, du Plessis M, Chen C, Choeurng V, Abdollah F, Robbins B, Ra S, Richert-Boe KE, Buerki C, Pearson K, Davicioni E, Weinmann S. Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community-based healthcare setting. The Journal of Urology. PMID 26626216 DOI: 10.1016/J.Juro.2015.11.044 |
0.468 |
|
| 2015 |
Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, et al. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446945 DOI: 10.1158/1078-0432.Ccr-15-0256 |
0.508 |
|
| 2015 |
Faisal FA, Sundi D, Tosoian JJ, Choeurng V, Alshalalfa M, Ross AE, Klein E, Den R, Dicker A, Erho N, Davicioni E, Lotan TL, Schaeffer EM. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location. European Urology. PMID 26443432 DOI: 10.1016/J.Eururo.2015.09.031 |
0.425 |
|
| 2015 |
Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, et al. Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Research. PMID 26294211 DOI: 10.1158/0008-5472.Can-15-0024 |
0.532 |
|
| 2015 |
Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks JL, Gupta N, Epstein JI, Netto GJ, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer E, ... Davicioni E, et al. Cyclin D1 Loss Distinguishes Prostatic Small Cell Carcinoma from Most Prostatic Adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26246306 DOI: 10.1158/1078-0432.Ccr-15-0744 |
0.451 |
|
| 2015 |
Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, et al. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26195723 DOI: 10.1200/Jco.2014.59.8912 |
0.532 |
|
| 2015 |
Goodwin JF, Kothari V, Drake JM, Zhao S, Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, Magee MS, Snook AE, Zhu Z, Den RB, Birbe RC, ... ... Davicioni E, et al. DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis. Cancer Cell. 28: 97-113. PMID 26175416 DOI: 10.1016/J.Ccell.2015.06.004 |
0.305 |
|
| 2015 |
Stoyanova R, Tachar M, Erho N, Lynne C, Abraham S, Patel M, Buerki C, Lam L, Jorda M, Kryvenko O, Ishkanian A, Abramowitz M, Davicioni E, Pollack A. TU-CD-BRB-12: Radiogenomics of MRI-Guided Prostate Cancer Biopsy Habitats. Medical Physics. 42: 3605. PMID 26128897 DOI: 10.1118/1.4925597 |
0.353 |
|
| 2015 |
Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L, Fedor HL, Glavaris S, Choeurng V, Buerki C, Erho N, Lam LL, Humphreys EB, Faraj S, Bezerra SM, et al. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. PMID 26058959 DOI: 10.1016/J.Eururo.2015.05.042 |
0.525 |
|
| 2015 |
Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli L, Li E, Collins C, et al. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies. Oncotarget. PMID 26041878 DOI: 10.18632/Oncotarget.3974 |
0.357 |
|
| 2015 |
Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, ... Davicioni E, et al. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 25986914 DOI: 10.1016/J.Ijrobp.2015.07.339 |
0.333 |
|
| 2015 |
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, et al. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology. PMID 25964175 DOI: 10.1016/J.Eururo.2015.04.033 |
0.547 |
|
| 2015 |
Ross AE, Yousefi K, Davicioni E, Ghadessi M, Johnson MH, Sundi D, Tosoian JJ, Han M, Humphreys EB, Partin AW, Walsh PC, Trock BJ, Schaeffer EM. Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology. PMID 25922274 DOI: 10.1016/J.Eururo.2015.04.016 |
0.401 |
|
| 2015 |
Alshalalfa M, Schliekelman M, Shin H, Erho N, Davicioni E. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer. Biology of the Cell / Under the Auspices of the European Cell Biology Organization. 107: 232-44. PMID 25900404 DOI: 10.1111/Boc.201400097 |
0.58 |
|
| 2015 |
Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choeurng V, Feng FY, Dicker AP, Lallas CD, Gomella LG, Davicioni E, Karnes RJ. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 944-51. PMID 25667284 DOI: 10.1200/Jco.2014.59.0026 |
0.434 |
|
| 2015 |
Klein EA, Yousefi K, Haddad Z, Choeurng V, Buerki C, Stephenson AJ, Li J, Kattan MW, Magi-Galluzzi C, Davicioni E. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. European Urology. 67: 778-86. PMID 25466945 DOI: 10.1200/Jco.2015.33.7_Suppl.154 |
0.56 |
|
| 2015 |
Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. European Urology. 67: 326-33. PMID 24998118 DOI: 10.1016/J.Eururo.2014.05.039 |
0.576 |
|
| 2015 |
Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. Bju International. 115: 419-29. PMID 24784420 DOI: 10.1111/Bju.12789 |
0.425 |
|
| 2015 |
Den R, Choeurng V, Howard L, De Hoedt A, du Plessis M, Yousefi K, Lam L, Buerki C, Trabulsi E, Dicker A, Davicioni E, Karnes J, Freedland S. Validation of a Genomic Classifier for Prediction of Metastasis Following Postoperative Salvage Radiation Therapy International Journal of Radiation Oncology*Biology*Physics. 93: S134. DOI: 10.1200/Jco.2016.34.2_Suppl.4 |
0.531 |
|
| 2015 |
Feng FY, Tomlins S, Alshalalfa M, Erho N, Yousefi K, Zhao S, Den RB, Dicker A, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Trock BJ, Demarzo A, ... Davicioni E, et al. Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes. Journal of Clinical Oncology. 33: 9-9. DOI: 10.1200/Jco.2015.33.7_Suppl.9 |
0.489 |
|
| 2015 |
Pollack A, Erho N, Noronha R, Lam LL, Buerki C, Abraham S, Klein EA, Karnes RJ, Den RB, Dicker A, Ishkanian A, Davicioni E, Feng FY, Stoyanova R. A biomarker panel associated with distant metastasis in prostate cancer patients treated with radiotherapy as prognostic for DM in a large cohort of prostatectomy patients. Journal of Clinical Oncology. 33: 8-8. DOI: 10.1200/Jco.2015.33.7_Suppl.8 |
0.525 |
|
| 2015 |
Feng FY, Zhao S, Prensner J, Erho N, Schipper MJ, Shi Y, Magi-Galluzzi C, Siddiqui J, Davicioni E, Den RB, Dicker A, Karnes RJ, Wei JT, Klein EA, Jenkins RB, et al. Investigating the long noncoding RNA SChLAP1 as a prognostic tissue and urine biomarker in prostate cancer. Journal of Clinical Oncology. 33: 7-7. DOI: 10.1200/Jco.2015.33.7_Suppl.7 |
0.548 |
|
| 2015 |
Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen SG, Stephens C, Kim P, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, et al. Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype. Journal of Clinical Oncology. 33: 29-29. DOI: 10.1200/Jco.2015.33.7_Suppl.29 |
0.545 |
|
| 2015 |
Stoyanova R, Pollack A, Lynne C, Jorda M, Erho N, Lam LL, Buerki C, Davicioni E, Ishkanian A. Using radiogenomics to characterize MRI-guided prostate cancer biopsy heterogenity. Journal of Clinical Oncology. 33: 25-25. DOI: 10.1200/Jco.2015.33.7_Suppl.25 |
0.525 |
|
| 2015 |
Ross A, Yousefi K, Trock BJ, Choeurng V, Lam LL, Fedor HL, Ghadessi M, Buerki C, Glavaris S, Sundi D, Tosoian J, Han M, Humphreys EB, Partin AW, Netto GJ, ... Davicioni E, et al. Validation of the Decipher prostate cancer classifier in intermediate to high-risk men treated with radical prostatectomy but without additional therapy upon PSA rise. Journal of Clinical Oncology. 33: 173-173. DOI: 10.1200/jco.2015.33.7_suppl.173 |
0.491 |
|
| 2015 |
Davicioni E, Choeurng V, Luo B, Yousefi K, Shin H, Haddad Z, Ross A, Schaeffer EM, Den RB, Dicker A, Karnes RJ, Thompson DJS. Recalibration of genomic risk prediction models in prostate cancer to improve individual-level predictions. Journal of Clinical Oncology. 33: e16122-e16122. DOI: 10.1200/Jco.2015.33.15_Suppl.E16122 |
0.513 |
|
| 2015 |
Lee HJ, Godebu E, Raheem O, Wang S, Yousefi K, Lam LL, Haddad Z, Alshalalfa M, Davicioni E, Shabaik A, Kane CJ. Evaluation of a genomic classifier in primary tumor and lymph node metastases in pre- and post-radical prostatectomy tissue specimens from patients with lymph node positive prostate cancer. Journal of Clinical Oncology. 33: e16087-e16087. DOI: 10.1200/Jco.2015.33.15_Suppl.E16087 |
0.535 |
|
| 2015 |
Ross A, Johnson MH, Yousefi K, Davicioni E, Fedor HL, Glavaris S, Choeurng V, Buerki C, Lam LL, Erho N, Humphreys EB, Netto GJ, Han M, Partin AW, Trock BJ, et al. Tissue-based genomics to augment post-prostatectomy risk stratification in a natural history cohort. Journal of Clinical Oncology. 33: 5059-5059. DOI: 10.1200/Jco.2015.33.15_Suppl.5059 |
0.501 |
|
| 2015 |
Seiler R, Choi W, Lam LL, Erho N, Buerki C, Davicioni E, Thalmann GN, McConkey DJ, Black PC. Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin. Journal of Clinical Oncology. 33: 4512-4512. DOI: 10.1200/Jco.2015.33.15_Suppl.4512 |
0.429 |
|
| 2015 |
Alshalalfa M, Tomlins SA, Erho N, Yousefi K, Zhao S, Den RB, Dicker AP, Trock B, DeMarzo A, Schaeffer EM, Ross A, Klein EA, Magi-Galluzzi C, Karnes JR, Jenkins RB, ... Davicioni E, et al. Abstract A1-64: Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-64 |
0.52 |
|
| 2015 |
Kothari V, Goodwin JF, Zhao S, Davicioni E, Karnes JR, Den RB, Mehra R, Knudsen KE, Feng FY. Abstract 2853: Investigating DNAPK as a biomarker and a novel therapeutic target in aggressive prostate cancer Cancer Research. 75: 2853-2853. DOI: 10.1158/1538-7445.Am2015-2853 |
0.503 |
|
| 2015 |
Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D, Singh A, Buerki C, Davicioni E, Hornberger J. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery Bju International. 115: 419-429. DOI: 10.1111/bju.12789 |
0.422 |
|
| 2015 |
Karnes J, Tomlins S, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den R, Dicker A, Trock B, Demarzo A, Ross A, Schaeffer E, Klein E, et al. 430 Molecular and clinical characterization of 1,577 primary prostate cancers reveal novel clinical and biological insights into subtypes European Urology Supplements. 14: e430-e430a. DOI: 10.1016/S1569-9056(15)60423-7 |
0.409 |
|
| 2015 |
Tomlins S, Alshalalfa M, Erho N, Yousefi K, Zhao S, den r, dicker a, trock b, Demarzo A, Ross A, Schaeffer E, Klein E, Magi-Galluzzi C, karnes j, Jenkins R, ... davicioni e, et al. MP6-09 MOLECULAR AND CLINICAL CHARACTERIZATION OF 1,577 PRIMARY PROSTATE CANCER TUMORS REVEALS NOVEL CLINICAL AND BIOLOGICAL INSIGHTS INTO ITS SUBTYPES Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.256 |
0.507 |
|
| 2015 |
Yamoah K, Johnson M, Choeurng V, Yousefi K, Haddad Z, Den R, Lal P, Feldman M, Dicker A, Klein E, Davicioni E, Rebbeck T, Schaeffer E. MP6-03 A NOVEL BIOMARKER SIGNATURE WHICH MAY PREDICT AGGRESSIVE DISEASE IN AFRICAN-AMERICAN MEN WITH PROSTATE CANCER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.250 |
0.526 |
|
| 2015 |
Seiler R, Lam L, Erho N, Davicioni E, Mitra AP, Skinner EC, Daneshmand S, Black PC. PD41-08 CAN BLADDER CANCER GENE EXPRESSION SIGNATURES BE USED TO PREDICT LYMPH NODE METASTASIS AT THE TIME OF RADICAL CYSTECTOMY? Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2416 |
0.429 |
|
| 2015 |
Faisal F, Sundi D, Ross A, Choeurng V, Erho N, Alshalalfa M, Davicioni E, Lotan T, Schaeffer E. MP66-16 ANATOMIC TUMOR LOCATION NOT RACIAL BACKGROUND IMPACTS ETS FAMILY TRANSCRIPTION FACTOR AND SPINK1 EXPRESSION IN PROSTATE CANCER. Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2369 |
0.468 |
|
| 2015 |
Johnson M, Ross A, Alshalalfa M, Erho N, Yousefi K, Choerung V, Glavaris S, Fedor H, Han M, Humphreys E, Partin A, Bezerra S, Faraj S, Netto G, Trock B, ... Davicioni E, et al. MP61-11 SPINK1 DEFINES A MOLECULAR SUBTYPE OF PROSTATE CANCER MEN WITH MORE RAPID PROGRESSION FROM BIOCHEMICAL RECURRENCE TO DEATH IN AN AT RISK, NATURAL HISTORY COHORT Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2192 |
0.485 |
|
| 2015 |
Faisal F, Sundi D, Ross A, Klein E, Den R, Dicker A, Choeurng V, Erho N, Alshalalfa M, Davicioni E, Lotan T, Schaeffer E. MP55-18 RACE IMPACTS ETS FAMILY TRANSCRIPTION FACTOR EXPRESSION IN PROSTATE CANCER: DATA FROM A MULTI-INSTITUTIONAL COHORT Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.2061 |
0.465 |
|
| 2015 |
Johnson M, Choeurng V, Yousefi K, Davicioni E, Klein E, Den R, Dicker A, Ross A, Schaeffer E. MP1-12 COMPARATIVE ANALYSIS OF AFRICAN AMERICAN AND EUROPEAN AMERICAN MEN USING A PROSTATE CANCER GENOMIC CLASSIFIER Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.175 |
0.51 |
|
| 2015 |
Ross A, Johnson M, Yousefi K, Trock B, Choeurng V, Lam L, Fedor H, Ghadessi M, Buerki C, Glavaris S, Sundi D, Tosoian J, Han M, Humphreys E, Partin A, ... ... Davicioni E, et al. 431 Validation of the Decipher® prostate cancer classifier in intermediate to high risk men treated with radical prostatectomy but without additional therapy upon PSA rise European Urology Supplements. 14: e431. DOI: 10.1016/J.Juro.2015.02.174 |
0.548 |
|
| 2015 |
Ross A, Johnson M, Yousefi K, Trock B, Choeurng V, Lam L, L. Fedor H, Ghadessi M, Buerki C, Glavaris S, Sundi D, Tosoian J, Han M, Humphreys E, Partin A, ... ... Davicioni E, et al. MP1-11 VALIDATION OF THE DECIPHER® PROSTATE CANCER CLASSIFIER IN INTERMEDIATE TO HIGH RISK MEN TREATED WITH RADICAL PROSTATECTOMY BUT WITHOUT ADDITIONAL THERAPY UPON PSA RISE Journal of Urology. 193. DOI: 10.1016/j.juro.2015.02.174 |
0.46 |
|
| 2015 |
Ross A, Bezerra S, Faraj S, Yousefi K, Fedor H, Glavaris S, Han M, Partin A, Humphreys E, Tosoian J, Johnson MH, Davicioni E, Trock B, Schaeffer E, Netto G. Mp53-17 Clinical Validation Of The 2005 Isup Gleason Grading System In A Cohort Of Intermediate And High Risk Men Undergoing Radical Prostatectomy The Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1711 |
0.43 |
|
| 2015 |
Johnson M, Yousefi K, Erho N, Choeurng V, Lam L, L. Fedor H, Davicioni E, Schaeffer E, Ross A. MP1-04 EVALUATION OF GENOMIC SIGNATURES IN INTERMEDIATE TO HIGH RISK MEN TREATED WITH RADICAL PROSTATECTOMY BUT WITHOUT ADDITIONAL THERAPY UPON PSA RISE Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.167 |
0.529 |
|
| 2015 |
Hu B, Fairey A, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim P, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins R, Den R, et al. MP37-19 AXIN2 EXPRESSION PREDICTS PROSTATE CANCER RECURRENCE AND MEDIATES AN INVASIVE, TUMORIGENIC PHENOTYPE Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1282 |
0.506 |
|
| 2015 |
Stoyanova R, Pollack A, Takhar M, Erho N, Lynne C, Lam L, Buerki C, Abraham S, Patel M, Jorda M, Kryvenko O, Abramowitz M, Davicioni E, Ishkanian A. Using Radiogenomics to Characterize MRI-Guided Prostate Cancer Biopsy Habitats International Journal of Radiation Oncology*Biology*Physics. 93: E235. DOI: 10.1016/j.ijrobp.2015.07.1140 |
0.418 |
|
| 2015 |
Pollack A, Erho N, Noronha R, Lam L, Buerki C, Abraham S, Klein E, Karnes J, Den R, Dicker A, Ishkanian A, Davicioni E, Feng F, Stoyanova R. A Biomarker Panel Associated With Distant Metastasis (DM) in Prostate Cancer Patients Treated With Radiation Therapy Is Also Prognostic for DM in a Large Cohort of Prostatectomy Patients International Journal of Radiation Oncology*Biology*Physics. 93: E217-E218. DOI: 10.1016/j.ijrobp.2015.07.1098 |
0.414 |
|
| 2014 |
Alshalalfa M, Crisan A, Vergara IA, Ghadessi M, Buerki C, Erho N, Yousefi K, Sierocinski T, Haddad Z, Black PC, Karnes RJ, Jenkins RB, Davicioni E. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. Bju International. PMID 25762434 DOI: 10.1111/Bju.13013 |
0.584 |
|
| 2014 |
Lalonde E, Ishkanian AS, Sykes J, Fraser M, Ross-Adams H, Erho N, Dunning MJ, Halim S, Lamb AD, Moon NC, Zafarana G, Warren AY, Meng X, Thoms J, Grzadkowski MR, ... ... Davicioni E, et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. The Lancet. Oncology. 15: 1521-32. PMID 25456371 DOI: 10.1016/S1470-2045(14)71021-6 |
0.601 |
|
| 2014 |
Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. The Lancet. Oncology. 15: 1469-80. PMID 25456366 DOI: 10.1016/S1470-2045(14)71113-1 |
0.534 |
|
| 2014 |
Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JM, Pauwels J, Park K, Kossai M, MacDonald TY, Fontugne J, Erho N, Vergara IA, Ghadessi M, ... Davicioni E, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature Communications. 5: 5383. PMID 25415230 DOI: 10.1038/Ncomms6383 |
0.54 |
|
| 2014 |
Mitra AP, Lam LL, Ghadessi M, Erho N, Vergara IA, Alshalalfa M, Buerki C, Haddad Z, Sierocinski T, Triche TJ, Skinner EC, Davicioni E, Daneshmand S, Black PC. Discovery and validation of novel expression signature for postcystectomy recurrence in high-risk bladder cancer. Journal of the National Cancer Institute. 106. PMID 25344601 DOI: 10.1093/Jnci/Dju290 |
0.633 |
|
| 2014 |
Den RB, Feng FY, Showalter TN, Mishra MV, Trabulsi EJ, Lallas CD, Gomella LG, Kelly WK, Birbe RC, McCue PA, Ghadessi M, Yousefi K, Davicioni E, Knudsen KE, Dicker AP. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. International Journal of Radiation Oncology, Biology, Physics. 89: 1038-46. PMID 25035207 DOI: 10.1016/J.Ijrobp.2014.04.052 |
0.478 |
|
| 2014 |
Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 5: 1434-8. PMID 24727738 DOI: 10.18632/Oncotarget.1846 |
0.548 |
|
| 2014 |
Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C, Sundi D, Mitra AP, Vergara IA, Thompson DJ, Triche TJ, Davicioni E, Bergstralh EJ, Jenkins RB, Karnes RJ, et al. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. Prostate Cancer and Prostatic Diseases. 17: 64-9. PMID 24145624 DOI: 10.1038/Pcan.2013.49 |
0.608 |
|
| 2014 |
Knudsen B, Simko JP, Lam LL, Erho N, Sierocinski T, Tenggara-Hunter I, Wellman H, Davicioni E, Chan JM, Carroll P, Kim HL, Cooperberg MR. Transcriptome-wide analysis of matched biopsy and prostatectomy to measure genomic classifiers of prostate cancer progression and field effect. Journal of Clinical Oncology. 32: 85-85. DOI: 10.1200/Jco.2014.32.4_Suppl.85 |
0.441 |
|
| 2014 |
Ferrari AC, Liu X, Alshalalfa M, Gomez-Pinillos A, Sierocinski T, Davicioni E. Effect of enzalutamide (EZ) exposure time on androgen receptor (AR) splice variant (SV) expression and gene transcription correlates in androgen-dependent (AD) prostate cancer (PC) cells. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E22066 |
0.392 |
|
| 2014 |
Mullane P, Duan Y, Benzon B, Simons B, Hurley P, Huang Z, Marchionni L, Vergara IA, Alshalalfa M, Davicioni E, Schaeffer EM, Ross A. An expression-guided screen for small molecules targeting aggressive prostate cancer. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E16081 |
0.56 |
|
| 2014 |
Ross A, Ghadessi M, Sundi D, Han M, Humphreys EB, Davicioni E, Partin AW, Walsh PC, Schaeffer EM. The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy. Journal of Clinical Oncology. 32: 5036-5036. DOI: 10.1200/Jco.2014.32.15_Suppl.5036 |
0.515 |
|
| 2014 |
Alshalalfa M, Vergara I, Erho N, Davicioni E, Jenkins R, Thomas K. Abstract 4720: Evaluation of a genomic classifier (Decipher®) in subsets of primary tumors with common prostate cancer genomic alterations Cancer Research. 74: 4720-4720. DOI: 10.1158/1538-7445.Am2014-4720 |
0.546 |
|
| 2014 |
Mitra A, Lam L, Ghadessi M, Erho N, Vergara I, Alshalalfa M, Haddad Z, Sierocinski T, Triche T, Skinner E, Davicioni E, Daneshmand S, Black P. 898 Discovery and validation of a novel expression signature for predicting recurrence in high-risk bladder cancer post-cystectomy European Urology Supplements. 13: e898. DOI: 10.1016/S1569-9056(14)60884-8 |
0.564 |
|
| 2014 |
Karnes R, Den R, Feng F, Showalter T, Mishra M, Trabulsi E, Lallas C, Gomella L, Birbe R, Mc Cue P, Ghadessi M, Buerki C, Davicioni E, Knudsen K, Dicker A. 205 Validation of a genomic classifier for predicting biochemical failure following post-operative radiation therapy in high-risk prostate cancer European Urology Supplements. 13: e205. DOI: 10.1016/S1569-9056(14)60202-5 |
0.42 |
|
| 2014 |
Trabulsi E, Karnes J, Feng F, Showalter T, Mishra M, Lallas C, Gomella L, Birbe R, McCue P, Ghadessi M, Buerki C, Davicioni E, Knudsen K, Dicker A, Den R. MP79-01 VALIDATION OF A GENOMIC CLASSIFIER FOR PREDICTING CLINICAL PROGRESSION FOLLOWING POST-OPERATIVE RADIATION THERAPY IN HIGH-RISK PROSTATE CANCER Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2504 |
0.545 |
|
| 2014 |
Ross A, Ghadessi M, Sundi D, Han M, Humphreys E, Davicioni E, Partin A, Walsh P, Schaeffer E. PD34-07 NATURAL HISTORY OF PROGRESSION TO PSA RECURRENCE AND METASASIS AMONG AT RISK MEN FOLLOWING RADICAL PROSTATECTOMY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2432 |
0.373 |
|
| 2014 |
Magi-Galluzzi C, Li J, Stephenson A, Yousefi K, Davicioni E, Kattan M, Klein E. MP74-06 INDEPENDENT VALIDATION OF A GENOMIC CLASSIFIER IN AN AT RISK POPULATION OF MEN CONSERVATIVELY MANAGED AFTER RADICAL PROSTATECTOMY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2339 |
0.384 |
|
| 2014 |
Mitra AP, Lam LL, Ghadessi M, Erho N, Vergara IA, Alshalalfa M, Haddad Z, Sierocinski T, Triche TJ, Skinner EC, Davicioni E, Daneshmand S, Black PC. MP39-09 A COMBINATION OF GENOMIC MARKERS AND CLINICAL VARIABLES PROVIDES SUPERIOR PROGNOSTIC PERFORMANCE IN HIGH-RISK BLADDER CANCER FOLLOWING CYSTECTOMY Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.1324 |
0.62 |
|
| 2014 |
Zhao S, Prensner J, Erho N, Ghadessi M, Yousefi K, Wellman H, Mehra R, Den R, Dicker A, Klein E, Jenkins R, Chinnaiyan A, Davicioni E, Feng F. Identification and Validation of the Long Noncoding RNA SChLAP1 as a Prognostic Biomarker in Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S2. DOI: 10.1016/J.Ijrobp.2014.06.020 |
0.394 |
|
| 2014 |
Den R, Karnes R, Feng F, Showalter T, Mishra M, Trabulsi E, Lallas C, Gomella L, Birbe R, McCue P, Yousefi K, Ghadessi M, Davicioni E, Kelly W, Knudsen K, et al. Validation of a Genomic Classifier for Predicting Metastasis Following Postoperative Radiation Therapy in High-Risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 90: S157. DOI: 10.1016/J.Ijrobp.2014.05.641 |
0.335 |
|
| 2014 |
Trifiletti D, Mason J, Den R, Dicker A, Buerki C, Davicioni E, Crisan A, Showalter T. Reconsidering Adjuvant Versus Salvage Radiation Therapy for Prostate Cancer Using an Individualized Decision Analysis With Genomic Classifier Scores International Journal of Radiation Oncology*Biology*Physics. 90: S585. DOI: 10.1016/j.ijrobp.2014.05.1759 |
0.403 |
|
| 2013 |
Thompson DJ, Mitra AP, Ghadessi M, Buerki C, Davicioni E, Wood PJ. Evaluation of a genomic-based prognostic test for metastasis in high-risk post-prostatectomy patients: Does it impact physician decision making? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 196. PMID 28137182 DOI: 10.1200/Jco.2013.31.6_Suppl.196 |
0.556 |
|
| 2013 |
Crisan A, Mitra AP, Ghadessi M, Buerki C, Davicioni E. A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 60. PMID 28137090 DOI: 10.1200/Jco.2013.31.6_Suppl.60 |
0.589 |
|
| 2013 |
Ghadessi M, Davicioni E, Crisan A, Buerki C, Erho N, Mitra AP, Thompson DJ, Triche TJ, Schaeffer EM, Feng FY. Validation of a genomic classifier that predicts metastatic disease progression in men with biochemical recurrence post radical prostatectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 52. PMID 28137052 DOI: 10.1200/Jco.2013.31.15_Suppl.5033 |
0.672 |
|
| 2013 |
Bergstralh EJ, Erho N, Crisan A, Davicioni E, Buerki C, Mitra AP, Thompson DJ, Carlson R, Haddad Z, Zimmermann B, Ballman KV, Kollmeyer TM, Sierocinski T, Vergara IA, Triche TJ, et al. Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 36. PMID 28136987 DOI: 10.1200/Jco.2013.31.6_Suppl.36 |
0.63 |
|
| 2013 |
Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics. 45: 1392-8. PMID 24076601 DOI: 10.1038/Ng.2771 |
0.677 |
|
| 2013 |
Wiseman SM, Haddad Z, Walker B, Vergara IA, Sierocinski T, Crisan A, Ghadessi M, Dao P, Zimmermann B, Triche TJ, Erho N, Davicioni E. Whole-transcriptome profiling of thyroid nodules identifies expression-based signatures for accurate thyroid cancer diagnosis. The Journal of Clinical Endocrinology and Metabolism. 98: 4072-9. PMID 23928671 DOI: 10.1210/Jc.2013-1991 |
0.564 |
|
| 2013 |
Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, ... ... Davicioni E, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. Plos One. 8: e66855. PMID 23826159 DOI: 10.1371/Journal.Pone.0066855 |
0.728 |
|
| 2013 |
Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. The Journal of Urology. 190: 2047-53. PMID 23770138 DOI: 10.1016/J.Juro.2013.06.017 |
0.688 |
|
| 2013 |
Badani K, Thompson DJ, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger J. Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group. Oncotarget. 4: 600-9. PMID 23592338 DOI: 10.18632/Oncotarget.918 |
0.51 |
|
| 2013 |
Badani KK, Thompson DJS, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra AP, Wood PJ, Hornberger JC. Impact of a genomic classifier of metastatic risk on treatment recommendations post-radical prostatectomy: Report from the DECIDE study group. Journal of Clinical Oncology. 31: e16044-e16044. DOI: 10.1200/Jco.2013.31.15_Suppl.E16044 |
0.489 |
|
| 2013 |
Schaeffer EM, Vergara IA, Crisan A, Erho N, Ghadessi M, Feng FY, Davicioni E, Ross AE. The role of advanced genetic testing in the management of prostate cancer post radical prostatectomy. Journal of Clinical Oncology. 31: 5089-5089. DOI: 10.1200/Jco.2013.31.15_Suppl.5089 |
0.598 |
|
| 2013 |
Mitra AP, Erho N, Lam LL, Vergara IA, Sierocinski T, Zimmermann B, Haddad Z, Ghadessi M, Crisan A, Triche TJ, Daneshmand S, Buerki C, Davicioni E, Black PC. Development of a genomic-clinical classifier for predicting progression after radical cystectomy in patients with muscle invasive bladder cancer. Journal of Clinical Oncology. 31: 4542-4542. DOI: 10.1200/Jco.2013.31.15_Suppl.4542 |
0.636 |
|
| 2013 |
Cooperberg M, Crisan A, Mitra A, Ghadessi M, Buerki C, Davicioni E. 2243 COMBINED VALUE OF GENOMIC BIOMARKERS AND CAPRA-S IN PREDICTING PROSTATE CANCER DEATH IN A HIGH-RISK SURGICAL COHORT Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2152 |
0.54 |
|
| 2013 |
Ross AE, Ghadessi M, Davicioni E, Crisan A, Buerki C, Erho N, Mitra AP, Thompson DJ, Triche TJ, Feng FY, Schaeffer EM. 2240 PERFORMANCE OF A GENOMIC CLASSIFIER THAT PREDICTS METASTATIC DISEASE PROGRESSION IN MEN WITH BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2149 |
0.605 |
|
| 2013 |
Crisan A, Vergara I, Ghadessi M, Thompson D, Buerki C, Erho N, Siercocinski T, Haddad Z, Black P, Mitra A, Davicioni E, Jenkins R. 2239 Clinical And Genomic Analysis Of Metastatic Disease Progression In A Background Of Biochemical Recurrence The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2148 |
0.403 |
|
| 2013 |
Dolginow D, Crisan A, Buerki C, Ghadessi M, Mitra AP, Erho N, Vergara IA, Haddad Z, Sierocinski T, Triche TJ, Davicioni E. 2230 EVALUATION OF A GENOMIC CLASSIFIER FOR IMPROVED RISK STRATIFICATION IN PROSTATE CANCER PATIENTS WITH SPECIFIC ADVERSE PATHOLOGIES AFTER SURGERY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2139 |
0.673 |
|
| 2013 |
Ross A, Ghadessi M, Crisan A, Buerki C, Erho N, Vergara I, Haddad Z, Harko S, Mitra A, Thompson D, Triche T, Davicioni E, Schaeffer E. 2229 COMPARISON OF CLINICAL AND GENOMIC MODELS FOR PREDICTION OF RAPID METASTATIC DISEASE AFTER RADICAL PROSTATECTOMY Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2138 |
0.573 |
|
| 2013 |
Karnes RJ, Ghadessi M, Bergstralh EJ, Erho N, Crisan A, Davicioni E, Buerki C, Mitra AP, Thompson DJS, Carlson R, Haddad Z, Zimmermann B, Ballman KV, Kollmeyer TM, Sierocinski T, et al. 2130 Validation Of A Genomic Classifier That Predicts Metastatic Disease Progression In Men With High Risk Pathological Features Post-Prostatectomy The Journal of Urology. 189. DOI: 10.1016/J.Juro.2013.02.2039 |
0.61 |
|
| 2013 |
Feng F, Ghadessi M, Davicioni E, Crisan A, Erho N, Mitra A, Triche T, Jenkins R, Ross A, Schaeffer E. Validation of a Genomic Classifier That Predicts Metastatic Disease Progression in Men With Biochemical Recurrence Post-Radical Prostatectomy International Journal of Radiation Oncology*Biology*Physics. 87: S125. DOI: 10.1016/J.Ijrobp.2013.06.323 |
0.56 |
|
| 2012 |
Jenkins RB, Bergstralh EJ, Davicioni E, Karnes RJ, Ballman KV, Fink S, Black PC, Ghadessi M, Triche TJ, Klee GG, Kollmeyer TM, Vergara IA, Crisan A, Erho N, Sierocinski T, et al. Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 175. PMID 28143156 DOI: 10.1200/jco.2012.30.5_suppl.175 |
0.664 |
|
| 2012 |
Vergara IA, Buerki C, Ghadessi M, Crisan A, Sierocinski T, Haddad Z, Zimmermann B, Harko S, Sosu-Sedzorme W, Triche TJ, Jenkins RB, Davicioni E. Development and validation of a digital Gleason score biomarker signature for risk stratification of patients with prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 40. PMID 28142490 DOI: 10.1200/Jco.2012.30.30_Suppl.40 |
0.665 |
|
| 2012 |
Ghadessi M, Buerki C, Vergara IA, Thompson DJ, Erho N, Sierocinski T, Haddad Z, Zimmermann B, Sosu-Sedzorme W, Harko S, Black PC, Davicioni E, Jenkins RB. Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 90. PMID 28142462 DOI: 10.1200/Jco.2012.30.30_Suppl.90 |
0.578 |
|
| 2012 |
Vergara IA, Buerki C, Ghadessi M, Crisan A, Sierocinski T, Haddad Z, Zimmermann B, Harko S, Sosu-Sedzorme W, Triche TJ, Davicioni E. Discovery of a biomarker signature that predicts upgrading or upstaging in patients with low-risk prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 37. PMID 28142405 DOI: 10.1200/Jco.2012.30.30_Suppl.37 |
0.663 |
|
| 2012 |
Jenkins RB, Bergstralh EJ, Davicioni E, Karnes RJ, Ballman KV, Fink S, Black PC, Ghadessi M, Triche TJ, Klee GG, Kollmeyer TM, Vergara IA, Crisan A, Erho N, Sierocinski T, et al. Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 175. PMID 27968097 DOI: 10.1200/Jco.2012.30.5_Suppl.175 |
0.7 |
|
| 2012 |
Erho N, Buerki C, Triche TJ, Davicioni E, Vergara IA. Transcriptome-wide detection of differentially expressed coding and non-coding transcripts and their clinical significance in prostate cancer. Journal of Oncology. 2012: 541353. PMID 22956952 DOI: 10.1155/2012/541353 |
0.67 |
|
| 2012 |
Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proceedings of the National Academy of Sciences of the United States of America. 109: 14977-82. PMID 22927397 DOI: 10.1073/Pnas.1203525109 |
0.575 |
|
| 2012 |
Vergara IA, Erho N, Triche TJ, Ghadessi M, Crisan A, Sierocinski T, Black PC, Buerki C, Davicioni E. Genomic "Dark Matter" in Prostate Cancer: Exploring the Clinical Utility of ncRNA as Biomarkers. Frontiers in Genetics. 3: 23. PMID 22371711 DOI: 10.3389/Fgene.2012.00023 |
0.666 |
|
| 2012 |
Ng TL, Leprivier G, Robertson MD, Chow C, Martin MJ, Laderoute KR, Davicioni E, Triche TJ, Sorensen PH. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death and Differentiation. 19: 501-10. PMID 21941369 DOI: 10.1038/Cdd.2011.119 |
0.386 |
|
| 2012 |
Buerki C, Mitra AP, Black PC, Ghadessi M, Bergstralh EJ, Erho N, Carlson R, Crisan A, Sierocinski T, Zimmermann B, Haddad Z, Vergara IA, Ballman KV, Klee GG, Fink S, ... ... Davicioni E, et al. Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer. Journal of Clinical Oncology. 30: 4565-4565. DOI: 10.1200/Jco.2012.30.15_Suppl.4565 |
0.666 |
|
| 2012 |
Crisan A, Davicioni E, Karnes RJ, Jenkins RB, Ghadessi MH, Buerki C, Bergstrahl EJ, Erho N, Vergara IA, Ballman KV, Black PC, Triche TJ. Abstract PR4: Biochemical recurrence is not a definitive surrogate endpoint for development of clinically useful predictive models for post-prostatectomy patients Cancer Research. 72: PR4-PR4. DOI: 10.1158/1538-7445.Prca2012-Pr4 |
0.594 |
|
| 2012 |
Erho N, Sierocinski T, Davicioni E, Jenkins RB, Gadhessi M, Buerki C, Vergara IA, Crisan A, Haddad Z, Zimmermann B, Mitra A, Triche TJ. Abstract B46: Identification of biomarkers for stratification of Gleason score 7 patients using whole-transcriptome expression profiling Cancer Research. 72: B46-B46. DOI: 10.1158/1538-7445.Prca2012-B46 |
0.663 |
|
| 2012 |
Mitra AP, Buckley JD, Mitra SA, Davicioni E, Anderson JR, Kapranov P, Skapek SX, Hawkins DS, Triche TJ. Abstract A23: A non-coding RNA panel predicts intermediate-risk childhood rhabdomyosarcoma prognosis better than standard pathologic criteria and coding genes Cancer Research. 72: A23-A23. DOI: 10.1158/1538-7445.Nonrna12-A23 |
0.557 |
|
| 2012 |
Mitra AP, Buckley JD, Mitra SA, Davicioni E, Anderson JR, Kapranov P, Skapek SX, Hawkins DS, Triche TJ. Abstract 5581: A non-coding RNA panel is prognostically superior to standard pathologic criteria and coding transcripts in rhabdomyosarcoma Cancer Research. 72: 5581-5581. DOI: 10.1158/1538-7445.Am2012-5581 |
0.558 |
|
| 2012 |
Ghadessi M, Bergstralh E, Buerki C, Black P, Erho N, Crisan A, Mitra A, Davicioni E, Feng F, Jenkins R. Validation of a Genomic-Clinical Classifier for Predicting Clinical Progression in Postprostatectomy High-risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S58-S59. DOI: 10.1016/J.Ijrobp.2012.07.359 |
0.482 |
|
| 2011 |
Rodeberg DA, Garcia-Henriquez N, Lyden ER, Davicioni E, Parham DM, Skapek SX, Hayes-Jordan AA, Donaldson SS, Brown KL, Triche TJ, Meyer WH, Hawkins DS. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1304-11. PMID 21357792 DOI: 10.1200/Jco.2010.29.4611 |
0.433 |
|
| 2011 |
Witkiewicz AK, Ertel A, Kline J, Davicioni E, Knudsen ES. Abstract 3906: Gene expression profiling of ductal carcinoma in situ reveals novel alterations in the tumor and stromal compartments related to progession and outcome of invasive breast cancer Cancer Research. 71: 3906-3906. DOI: 10.1158/1538-7445.Am2011-3906 |
0.366 |
|
| 2011 |
Jenkins R, Crisan A, Erho N, Ballman K, Bergstralh E, Fink S, Kollmeyer T, Buerki C, Black P, Davicioni E. OP 29 Development of a genomic-clinical classifier model for predicting clinical recurrence in patients with localized prostate cancer European Journal of Cancer. 47: S8-S9. DOI: 10.1016/S0959-8049(11)72623-5 |
0.553 |
|
| 2010 |
Abdueva D, Wing M, Schaub B, Triche T, Davicioni E. Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affymetrix microarrays. The Journal of Molecular Diagnostics : Jmd. 12: 409-17. PMID 20522636 DOI: 10.2353/Jmoldx.2010.090155 |
0.49 |
|
| 2010 |
Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ. Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1240-6. PMID 20124188 DOI: 10.1200/Jco.2008.21.1268 |
0.485 |
|
| 2010 |
Mendoza M, Ren L, Davicioni E, Wai D, Triche T, Khanna C. Abstract 2357: Defining the Ezrin-CLIC4 interaction in osteosarcoma Cancer Research. 70: 2357-2357. DOI: 10.1158/1538-7445.Am10-2357 |
0.52 |
|
| 2009 |
Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, Sorokin A, Ovchinnikov LP, Davicioni E, Triche TJ, Sorensen PH. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 15: 402-15. PMID 19411069 DOI: 10.1016/J.Ccr.2009.03.017 |
0.516 |
|
| 2009 |
Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ. Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. The American Journal of Pathology. 174: 550-64. PMID 19147825 DOI: 10.2353/Ajpath.2009.080631 |
0.53 |
|
| 2008 |
Davicioni E, Wai DH, Anderson MJ. Diagnostic and prognostic sarcoma signatures. Molecular Diagnosis & Therapy. 12: 359-74. PMID 19035623 DOI: 10.1007/Bf03256302 |
0.356 |
|
| 2007 |
Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide. Journal of the National Cancer Institute. 99: 1107-19. PMID 17623797 DOI: 10.1093/Jnci/Djm044 |
0.461 |
|
| 2006 |
Wang JG, Barsky LW, Davicioni E, Weinberg KI, Triche TJ, Zhang XK, Wu L. Retinoic acid induces leukemia cell G1 arrest and transition into differentiation by inhibiting cyclin-dependent kinase-activating kinase binding and phosphorylation of PML/RARalpha. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 2142-4. PMID 16935935 DOI: 10.1096/Fj.06-5900Fje |
0.443 |
|
| 2006 |
Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Research. 66: 6936-46. PMID 16849537 DOI: 10.1158/0008-5472.Can-05-4578 |
0.542 |
|
| 2006 |
Yu Y, Davicioni E, Triche TJ, Merlino G. The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Research. 66: 1982-9. PMID 16488997 DOI: 10.1158/0008-5472.Can-05-2360 |
0.567 |
|
| Show low-probability matches. |